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Development and Characterization of LDV Peptide Targeted Nanocarriers for Paclitaxel
Delivery: A Comparative Study of Micelles, Liposomes and Solid Lipid Nanoparticles
Abstract
By Poonam Dattani
University of the Pacific
2019
Nanocarriers have been established as delivery vehicles to target cancer tumors.
However, premature drug leakage is one of the major reasons for inefficient drug delivery of
nanocarriers to the tumor. Drug diffusion out of the nanocarriers or destabilization of drug
loaded nanocarriers by physiological interactions with blood cells, serum proteins, and cell
membranes upon systemic administration contribute to premature drug release. In this study,
targeted micelles, liposomes and solid lipid nanoparticles (SLNs) of similar composition
were prepared and characterized to compare physicochemical characteristics, in vitro
stability, in vitro release rates in release media and in vivo performance. Peptide
Amphiphiles (PAs) formed micelles with critical micelle concentration (CMC) values
ranging between 23.68 ± 0.72 µM to 38.76 ± 2.27 µM. Transmission Electron Microscopy
(TEM) images confirmed the self-assembly of PAs into spherical structures where the largest
sizes were seen for C16-(PEG2)6-LDV micelles. Dynamic Light Scattering (DLS) results
confirmed the presence of targeted liposomes and SLNs with sizes smaller than 100 nm.
Forster Resonance Energy Transfer (FRET) studies revealed that targeted micelles, liposomes
and SLNs were all stable upon dilution in aqueous medium, however the stability was
significantly reduced in human serum, with micelles being the least stable and SLNs being
the most stable. The same trend was observed for the in vitro release profiles, where targeted
paclitaxel-loaded micelles (PTX-micelles) had the fastest release rate and paclitaxel-loaded
SLNs (PTX-SLN) exhibited the slowest release rate. DLS results showed that sizes of PTX-
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SLNs were smaller than PTX-liposomes (80.53 ± 5.37 nm vs 123.31 ± 5.87 nm). Cryogenic
TEM observation showed increasing size in the order of PTX-micelles (6 to 12 nm) < PTXSLNs (10-120 nm) < PTX-liposomes (48-145 nm). Drug Loading Content (DLC) of PTXSLNs was greater than PTX-micelles and PTX-liposomes (7.45 ± 0.41 % vs 1.70 ± 0.42 %
and 0.92 ± 0.09 %). Compared to initial aqueous dispersions, reconstituted spray dried
formulations maintained their nanosize and paclitaxel content over 7 days at 4⁰C. In A375
melanoma xenograft mouse model, the tumor volumes were significantly smaller for mice
treated with PTX-SLNs compared to the control group. Furthermore, tumor volumes were
significantly smaller for mice treated with PTX-SLNs compared to those treated with PTXmicelles and PTX-liposomes. These studies demonstrate the potential of stable PTX-SLNs
for targeted delivery in cancer.
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Chapter 1: Introduction
1.1 Cancer: Chemotherapy and Limitations
Cancer is a disease characterized by the uncontrolled growth and spread of abnormal
cells and it is the leading cause of death worldwide, accounting for an estimated 9.6 million
deaths in 2018 [1]. The American Cancer Society (ACS) reported that in 2019, there will be
an estimated 1,762,450 new cancer cases diagnosed and 606,880 cancer deaths in the United
States [2]. It is also estimated that by 2030, 23.6 million new cases of cancer per year will
occur, compared to 17 million cases that occurred in 2016 [3]. Treatment modalities of
localized and metastasized cancer include immunological, photothermal, photodynamic, gene
and hormone therapy. Surgery, radiation and chemotherapy are the first line treatment
options for most types of cancer. Chemotherapeutic drugs have several limitations, for
example they lack specificity towards cancer cells which results in toxic effects to healthy
tissue, including bone marrow suppression, infertility and mucositis. Furthermore, the high
distribution volume results in high concentrations of these drugs in healthy tissue. The
development of anti-cancer drug formulations is challenging due to their poor aqueous
solubility. For example, paclitaxel is hydrophobic and has a very low water solubility (<0.3
mg/mL), which can result in aggregation upon intravenous administration causing
embolization of blood vessels. To overcome this issue, paclitaxel is currently formulated
with Cremophor EL and dehydrated ethanol which is diluted with saline prior to intravenous
administration. However, Cremophor EL is a toxic excipient and has been known to cause
severe side effects such as hypersensitivity reactions, nephrotoxicity, cardiotoxicity and
cardiotoxicity [4]. The efficacy of chemotherapeutic agents is also limited due to resistance
mechanisms. For example, increased hydrostatic pressure of the tumor interstitium of tumor
tissue can result in the outward convective interstitial flow resulting in drug transport away
from the tumor. Furthermore, cancer cells can acquire resistance to a wide variety of drugs
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through activation of anti-apoptotic pathways and over-expression of efflux pumps and this is
known as multidrug resistance (MDR). The main protein involved in MDR is P-glycoprotein
(P-gp), which is an ATP-dependent transporter located on the cell and nuclear membrane that
non-selectively binds to neutral or positively charged molecules, of which many
antineoplastic drugs fall under this category. The normal physiological role of P-gp is to
protect the cellular entry of undesirable molecules through efflux mechanisms and to
transport substances across the cells including drugs, steroids, polypeptides and bile acids.
However, P-gp is over-expressed in intestinal, liver, pancreas, kidney, ovary and testicular
cancers, which results in the pumping out of drug molecules from cells, resulting in suboptimal therapeutic drug concentrations at the tumor site [5-9]. Overall, these factors
highlight the necessity for new and more efficacious treatments for cancer.
1.2 Targeted Drug Delivery of Nanocarriers
Nanotechnology is an emerging therapeutic platform that is being used for the
treatment of cancer and has shown great promise in the past few decades. Nanocarriers have
gained increased interest over the years due to their ability to overcome obstacles faced with
conventional chemotherapy, such as non-specificity and severe side effects. Specifically,
nanocarriers are colloidal drug carrier systems less than 500 nm in size and can be used for
encapsulation and delivery of hydrophobic and hydrophilic anti-cancer agents to improve
bioavailability and therapeutic efficacy [10]. Several advantages of nanocarriers include,
improved pharmacokinetics, pharmacodynamics and bioavailability, improved solubility and
stability, ability to protect payload from degradation, facilitation of cellular uptake and
cellular internalization, decreased non-specific toxicity, controlled release and site-specific
delivery through active and passive targeting mechanisms. Furthermore, nanocarriers can
help to overcome MDR through bypassing of P-gp efflux pumps on the cellular membrane
[11].
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1.2.1 Passive targeting. Targeting of nanocarriers to the tumor tissue is highly
dependent on the structural differences of normal healthy tissue compared to tumor tissue.
The pathophysiological abnormalities in the tumor microenvironment allow for the selective
accumulation of nanocarriers into the tumor tissue. In healthy tissues, a counterbalance is
attained between proangiogenic molecules (VEGF) and antiangiogenic molecules
(VEGFR1). However, in tumor tissue, new vessels are formed and pro-angiogenic signaling
is abnormally upregulated to ensure that growing tumor cells receive an adequate supply of
oxygen and nutrients. This results in the formation of an abnormal vasculature network,
characterized by irregular, chaotic, tortuous and leaky blood vessels. The endothelial surface
is fenestrated with gaps (10 to 1000 nm) between the endothelial cells, enabling the
extravasation and selective accumulation of nanocarriers into the interstitial space. However,
tight junctions between normal endothelial cells do not allow nanocarriers to extravasate and
this difference can be exploited to achieve tumor targeted drug delivery. Furthermore, the
leaky tumor vasculature enables the extravasation of excess fluid into the tumor interstitium
and the inability of non-functional lymphatic vessels to drain the excess fluid leads to an
imbalance in the interstitial fluid pressure (IFP) [12, 13]. The increased vascular
permeability and poor lymphatic drainage results in the selective accumulation and retention
of nanocarriers in the tumor tissue and this is known as the Enhanced Permeability and
Retention (EPR) effect. Despite these advantages, nanocarrier accumulation and retention
may vary and have unpredictable outcomes due to the heterogeneity of tumor environment
and variation in the degree of tumor vascularization and angiogenesis. Additionally, the
elevated IFP of solid tumors may prevent the uptake and homogenous distribution of drugs in
the tumor. Furthermore, nanocarriers can be recognized as foreign and undergo opsonization
by the cells of the reticuloendothelial system (Mononuclear Phagocyte System, MPS). These
factors combined may potentially reduce the bioavailability of drug at the tumor site and
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reduce the efficacy of these drug delivery systems. Despite these limitations, there are
several passive targeted nanocarriers commercially available, which demonstrate the
potential of nanocarrier drug delivery systems in tumor therapy. Doxil and Myocet were the
first liposome products to be approved by the FDA for the treatment of cancer, and were
designed to improve the PK, PD and bioavailability of doxorubicin, which has a very short
elimination half-life of 0.2 hours [14]. Myocet is an un-PEGylated liposome product, which
demonstrated an improved elimination half-life of 2.5 hours. To further prolong the blood
circulation time PEGylated liposomes were formulated (Doxil) which significantly increased
the elimination half-life to 55 hours. Furthermore, Doxil has been shown to reduce
cardiotoxic effects significantly compared to free doxorubicin [14].
1.2.2

Active targeting. Passive targeting strategies have several limitations as

described above, therefore the development of nanocarriers with improved targeting abilities
is of interest. Active targeting strategies are employed by grafting or incorporating ligands
onto nanocarriers that specifically recognize and bind to receptors over-expressed in tumor
cells. This results in enhanced cellular internalization rather than increased tumor
accumulation. The most commonly studied targets and their ligands are listed in table 1.3
[15]. Integrins are transmembrane heterodimeric glycoprotein receptors comprising of 18 a
and 8 b polypeptide subunits which non-covalently assemble into 24 different combinations
[16]. Specifically, integrins mediate cell adhesion by interacting and binding to extracellular
matrix glycoproteins or connective tissue such as fibronectin. Integrin mediated adhesion
influences signaling cascades which in turn modulates standard cellular functions such as cell
growth, motility, differentiation and proliferation. Collectively, these functions are
fundamental to tissue integrity and the maintenance of normal cellular functions [17]. Many
integrin receptors are over-expressed in cancer cells, which has been shown to correlate with
tumor progression and growth [18]. For examples integrin a4b1 is over-expressed in
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melanoma cells making it an ideal target for selective delivery of chemotherapeutic agents to
cancer cells. This integrin recognizes a short peptide motif Leucine-Aspartic acid-Valine
(LDV) within ligands fibronectin and VCAM1, which is key for regulating biological activity
[19-22]. Therefore, employing synthetic peptides such as LDV could potentially be a useful
strategy to target anti-cancer agents to cancer cells [23]. Peptides provide various advantages
including therapeutic effects, small size to enhance delivery to the tumor, low risk of immune
reactivity, ease of synthesis and low cost. Furthermore, nanocarriers provide a good platform
for ligand conjugation through grafting or incorporation at controlled densities and
orientations.
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1.2.3

Factors influencing drug targeting and delivery of nanocarriers. The EPR

effect is influenced by the physicochemical properties of nanocarriers, including size, shape
and surface charge and this in turn affects cellular uptake, internalization and circulation halflife. To increase the efficacy of drug targeting and delivery, the physicochemical properties
of nanocarriers can be optimized to an ideal range (table 1.4).
a) Size. Nanocarriers with sizes above 400 nm will not be able to extravasate into
the leaky fenestrations of the endothelial cells due to entrapment in the liver and spleen and
phagocytosis by macrophages and Kupffer cells of the MPS. Conversely, nanocarrier sizes
that are too small (<6 nm) are likely to be excreted by the kidneys. Larger particles of around
100 nm may not be able to penetrate deep into the finer vasculature and tissues of the tumor,
compared to smaller sized nanocarriers of around 20 nm [24]. Cellular uptake is significantly
influenced by the size of nanocarriers and this was demonstrated by preparing chitosan
nanoparticles of various sizes and characterizing cellular uptake. The results showed reduced
non-phagocytic cellular internalization at sizes above 150 nm and increased phagocytic
cellular uptake with sizes above 150 nm [25]. Taking these factors into consideration, ideal
nanocarrier sizes range between 10 nm to 100 nm for optimal drug targeting and delivery.
b) Surface charge. The surface charge of nanocarriers also influences phagocytic
and non-phagocytic cellular uptake, agglomeration, blood circulation time, opsonization and
renal elimination. In general, nanocarriers with a zeta potential ≥ + 30 mV or ≤ - 30 mV are
preferred to maintain good colloidal stability and prevent aggregation in a physiological
environment. Positively charged nanocarriers are taken up by cells more effectively
compared to neutral or negatively charged nanocarriers due to the strong interactions with the
negatively charged cell membrane. For example, it was reported that positively charged
chitosan nanoparticles were more readily internalized in non-phagocytic cells compared to
negatively charged nanoparticles [25]. However, positively charged nanocarriers are known
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to have increased blood clearance and cause hemolysis and aggregation of platelets, due to
opsonization and recognition by the MPS [24]. Also, various positively charged lipids used
for formulating nanocarriers are cytotoxic through destabilization of the cell membrane,
therefore careful consideration must be given when selecting materials for formulating
nanocarriers. Overall, neutral or negatively charged nanocarriers are preferred due to
prolonged circulation time, reduced cytotoxicity and evasion of renal elimination.
c) Shape. Less extensively studied is the role of nanoparticle geometry on
drug targeting and delivery. Most therapeutic carriers under investigation or in clinical
practice are spherical in shape and this is due to the presumption that size is the principle
parameter of interest and there is a difficulty in developing methods for non-spherical
nanoparticles. The shape of nanoparticles can affect velocity, diffusion and adhesion to
blood vessel walls. The targeting ability is also affected due to the available surface area for
targeting ligands and the degree to which particles fit contours of target cell membranes. The
role of geometry on phagocytosis has been studied, where polystyrene nanoparticles of
various shapes were prepared and tested in alveolar rat macrophages. Results showed that
internalization of ellipse-shaped nanoparticles was dependent on the point of attachment,
where internalization occurred within a few minutes from the pointed end and no
internalization when in contact with the flat side. For spherical polystyrene nanoparticles,
internalization into macrophages occurred at all points of attachment due to symmetry [26].
These results showed that development of non-spherical nanoparticles may prove to be a
useful strategy for evading phagocytosis. The role of geometry on non-phagocytic cellular
internalization in human cervical carcinoma epithelial HELA cells has also been studied
through formulation of cubed and cylindrical nanoparticles of various sizes and shapes.
Results showed that rod-shaped, high aspect ratio (AR=3, d=150 nm, h=450 nm)
nanoparticles internalized much faster compared to rod-shaped particles with a lower aspect
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ratio (AR=1, d=200 nm, h=200 nm) [27]. A possible explanation for this is that higher aspect
ratio particles have larger surface areas for contact with the cell membrane, resulting in faster
cellular uptake. This is highlighted by another study that reported that antibody coated rodshaped nanoparticles compared to spherical were more effective at targeting endothelial cells
due to the large surface area and thus increased interactions of antibody binding sites to cell
membrane receptors [28].
d) Surface chemistry. It is well known that less than 10% of nanocarriers
administered intravenously can reach their target site and this partially due to removal by the
MPS in the liver and spleen. Opsonization occurs when antibodies or other substances bind
to foreign particles, making them more susceptible to phagocytosis and these opsonins
interact with nanocarriers through electrostatic, ionic, van der waals, hydrophobic and
hydrophilic forces [29]. In general, nanocarriers that are highly charged and hydrophobic are
more susceptible to opsonization, and it is therefore essential to modify the surface of
nanocarriers to help avoid elimination by the immune system and prolong the blood
circulation time. One of the most common strategies is to coat the surface of nanocarriers
with a hydrophilic polymer known as polyethylene glycol (PEG), to produce stealth
characteristics. In 1997, Abuchowski reported that PEGylation to bovine liver catalase
significantly reduced immunogenicity and prolonged blood circulation time and since then
PEG has been used frequently in nanocarriers such as micelles, liposomes and lipid
nanoparticles [30]. PEG forms a hydrophilic flexible layer on the surface of nanocarriers
which prevents adsorption of opsonins by steric hinderance and subsequent disruption of
nanocarriers. Depending on the molecular weight, PEG can form mushroom or brush-like
structures surrounding the nanocarriers. For example, low PEG (5KDa) densities between
0.5 to 0.7 mol% form mushroom-like structures to maximize surface coverage. At higher
densities, PEG chains extend to avoid overlap with existing PEG chains forming a brush-like
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model. There is an optimal range of PEG required to form stable nanocarriers, for example it
has been reported that thermodynamically stable liposomes are formed when formulated with
5 to 7 mol% PEG and further increases to above 10 mol% destabilize liposomes due to
repulsion between PEG chains [31]. The advantageous effects of PEG are clearly
demonstrated by the two commercially available liposome products Doxil (PEGylated) and
Myocet (non-PEGylated), where Doxil has a significantly longer blood circulation time
compared to Myocet [14]. It has also been reported that PEGylated polymeric nanoparticles
demonstrated higher plasma concentrations and reduced accumulation in the liver compared
to non-pegylated polymeric nanoparticles. Furthermore, 10% of nanoparticles were
remaining 6 hours post injection compared to only 0.4% for non-pegylated NP’s [32]. These
results clearly demonstrated the importance of modifying the surface of nanocarriers to
prolong circulation time and reduce uptake by the MPS.
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1.3 Nanocarriers
Nanocarriers are spherical aggregates, ranging between 20 nm to 400 nm in size and
are commonly used to encapsulate hydrophobic and hydrophilic drugs. Nanocarriers can be
classified into two categories: organic and inorganic nanoparticles. Examples of the latter
include carbon nanotubes and mesoporous silica nanoparticles, however these are less
common due to non-biocompatibility and toxicity. Organic nanocarriers include liposomes,
micelles, dendrimers, lipid and polymeric nanoparticles and these are generally preferred due
to low toxicity and biocompatibility of lipid and polymeric materials. Phospholipids are the
major component of the biological cell membrane, therefore their biocompatible and
biodegradable nature makes them key components in drug delivery systems. The selfassembly of lipids is dependent on the nature of the hydrophilic and hydrophobic regions and
the type of nanocarrier formed is largely dependent on the packing constraints of lipids to
minimize exposure of the hydrophobic regions to the aqueous environment. The geometry of
a nanocarrier is defined by the packing parameter, where V is the surfactant tail volume, a is
the effective area per molecule at the interface and l is the surfactant tail length [33].
Therefore, if these factors are known, the geometry of a nanocarrier can be predicted.

Equation

𝑃 = 𝑉/𝑙

When P=1, a lamellar liquid crystalline structure is formed giving rise to vesicle or liposome
formation. For example, the biological cell membrane is composed of phospholipids arranged
in a bilayer or lamellar structure. When P>1, amphiphilic lipids self-assemble to form
reversed structures such as reversed micelles, reversed hexagonal and reverse cubic
structures. Packing parameters <1 form normal micelle, hexagonal or cubic phases.
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1.3.1

Micelles. Micelles are nanosized (10 nm to 100 nm) colloidal aggregates that

result from the self-assembly of lipid or polymeric amphiphilic molecules in aqueous
solution. At low amphiphilic concentrations, amphiphiles exist as monomers and at higher
concentrations amphiphiles aggregate to form micelle structures and the concentration at
which this occurs is known as the Critical Micelle Concentration (CMC). Micelles are
dynamic structures that are in continuous equilibrium with monomers, where monomers are
continually being exchanged between micelles. During micelle formation, the hydrophobic
segments of amphiphiles aggregate to form a hydrophobic core that encapsulates and controls
the release of hydrophobic drugs. The hydrophilic segment forms a hydrophilic shell,
ensuring aqueous solubility, stabilization of the micelles and prevention of opsonization and
uptake by the MPS. Micelles have several advantages including increased solubility of
hydrophobic drugs and formulation using a variety of polymeric or lipid amphiphilic
molecules to fine-tune the CMC and stability of micelles. Furthermore, the small sizes of
micelles enable rapid accumulation into the tumor. Targeting ligands can be grafted onto
amphiphilic molecules to impart active targeting properties to improve drug targeting and
delivery to the tumor tissue. Despite these advantages, micelles have poor drug loading
efficiency and poor in vivo stability. For example, surfactant-based micelles exhibit high
CMC values leading to reduced stability when administered systemically [34]. For this
reason, various strategies have been employed to improve the stability of micelles including,
cross-linking and covalent drug entrapment [34, 35]. Compared to surfactant-based micelles,
polymeric micelles demonstrate significantly lower CMC values and self-assembly occurs at
concentrations exceeding the CMC. These systems demonstrate better stability and
prolonged circulation times in vivo [36, 37]. Some commonly used materials used to form
micelles include poloxamers, PEG-PLA polymers, PEGylated polyglutamic acid, PEG-PAA
and lipid-PEG conjugates.
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1.3.2

Liposomes. Liposomes are the most widely used nanocarrier systems and

represent the majority of FDA approved nanomedicine products (table 1.1, table 1.2).
Liposomes are formed from amphiphilic molecules, composed of a phospholipid bilayer that
entraps hydrophobic drugs and surrounds a hydrophilic core for entrapping hydrophilic
drugs. Liposomes can be formed from natural or synthetic lipids, where multiple bilayers
result in the formation of large multilamellar vesicles (MLV). These can be downsized to
single bilayer liposomes known as small unilamellar vesicles (SUV). Like micelles,
liposomes are versatile drug delivery systems as their lipid composition, size, charge and
surface chemistry can be fine-tuned to achieve optimal drug delivery characteristics.
Compared to micelles, the size range of liposomes tends to be larger, ranging between 50 nm
to 500 nm and this range depends on the method of production and the choice of lipids. The
surface charge of liposomes depends on the choice of lipids used, for example cationic and
anionic lipids will produce positively or negatively charged liposomes respectively. The
surface chemistry of liposomes can also be modified by coating with PEG polymers to help
evade the immune system and prolong blood circulation. Liposomes can also be grafted with
targeting ligands to impart specific targeting properties. Despite these advantages, drug
loading in liposomes remains a challenge, where encapsulation of hydrophilic drugs is low
and requires active loading techniques to increase the drug loading efficiency. Furthermore,
encapsulation of hydrophobic drugs inside the bilayer was shown to destabilize the lipid
bilayer membrane resulting in aggregation and instability of vesicles [38]. Like micelles,
liposomes also have the potential to become unstable upon in vivo administration. For
example, lipids with low transition temperatures result in a more fluid-like flexible membrane
structure which increases the permeability and drug leakage from the membrane at
physiological body temperature.
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1.3.3

Solid lipid nanoparticles. SLNs are nanosized colloidal structures with sizes

ranging from 50 to 1000 nm. Typically, SLNs are composed of a solid lipid phase stabilized
by a surfactant. Examples of lipids used are triglycerides, free fatty acids, fatty acid alcohols,
waxes and steroids, which are all used for dispersion and entrapment of hydrophobic drugs.
The lipid molecules are solid at room and body temperatures, which enables them to have
better stability and prolonged drug retention compared to micelles and liposomes. SLNs
have several advantages, that include excellent physically stability, good release profiles,
high drug loading capacity, biodegradability and non-toxicity of lipid carriers. However,
despite these advantages SLNs can become unstable through gelation, lipid particle growth
and polymorphic transitioning [39].
1.4 Significance and Statement of the Problem
Despite the development of numerous anti-cancer nanocarriers in the pre-clinical
phase, very few have been successfully developed and approved for clinical use. This is due
to the low delivery efficiencies of anti-cancer nanomedicines to the tumor which is
highlighted by a recent meta-analysis of pre-clinical data suggesting that a median of 0.7% of
the injected dose of nanocarriers reaches the target tumors [40, 41]. One of the major reasons
for low delivery to the tumor is the poor stability of anti-cancer drug-loaded nanocarriers.
Upon systemic administration, drug diffusion out of the nanocarriers or interactions with
blood cells, cellular membranes, serum proteins and other biomacromolecules can result in
premature drug release before reaching the target tumor site. Therefore, developing a stable
anti-cancer nanocarrier system is key for the successful clinical translation of these
nanomedicines.
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1.5 Purpose
The purpose of this dissertation is to develop targeted micelles, liposomes and SLNs
of similar composition and to evaluate their potential by comparing physicochemical
characteristics, in vitro stability, in vitro release rates and in vivo efficacy. These studies will
provide a more comprehensive evaluation of the stability of different types of nanocarrier
systems, providing further insights into the selection of suitable nanocarrier systems for
clinical development.
1.6 Specific Aims
The specific aims of this dissertation are as follows:
Aim 1: To design, prepare and characterize LDV-targeted micelles, liposomes and solid lipid
nanoparticles of similar composition.
Aim 2: To compare the in vitro stability and in vitro drug release of LDV-targeted micelles,
liposomes and solid lipid nanoparticles. The stability of micelles, liposomes and solid lipid
nanoparticles can be assessed in aqueous medium and biological media using Forster
Resonance Energy Transfer (FRET). Anti-cancer drug paclitaxel can be loaded into micelles,
liposomes and solid lipid nanoparticles and in vitro release characteristics can be determined.
Nanocarriers can also be spray dried to maintain long-term stability.
Aim 3: To compare the in vivo anti-tumor efficacy of selected LDV-targeted paclitaxelloaded micelles, liposomes and solid lipid nanoparticles using mouse tumor models.
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Chapter 2: Design and Synthesis of LDV Peptide Amphiphiles
2.1 Introduction
Amphiphiles are composed of hydrophobic and hydrophilic regions which selfassemble in aqueous solutions to form a variety of structures including micelles and vesicles.
Amphiphiles can be characterized by the hydrophilic-lipophilic balance (HLB), which is an
empirical parameter indicating the degree of hydrophilicity and lipophilicity. HLB is related
to the number, weight of hydrophobic and lipophilic groups as well as the structure of the
amphiphile and there are several methods that can be used to determine this value [42].
Typically, for non-ionic surfactants, the HLB scale ranges between 1 and 20. For ionic
surfactants, the HLB scale ranges between 0 to 40, where 0 indicates complete
hydrophobicity and 40 indicates a stronger hydrophilic character of the amphiphile. The
HLB of amphiphiles must be optimum to enable formation of micelles and this can be
achieved by altering the hydrophobic and hydrophilic segments. Therefore, determination of
HLB values can be used to predict surfactant properties and those surfactants with HLB
values within the scale can be used to assess the potential self-assembly into micelles. In this
study, novel PAs were designed, where the hydrophobic region is composed of a C16 fatty
acid chain and the hydrophilic region is comprised of tripeptide LDV targeting region and
ethylene oxide linker units (Figure 2.1). PAs were selected for synthesis based on optimum
HLB values and assessed for their ability to form micelles. The general process of Solid
Phase Peptide Synthesis (SPPS) is illustrated in figure 2.2 and involves the building of a
peptide chain on a solid resin. The first amino acid already attached to the resin is coupled
with subsequent amino acids using a series of deprotection and coupling steps. Specifically,
this involves the deprotection of temporary protecting groups on the N-terminal of the resinattached amino acid and subsequent coupling of the next amino acid. This process is
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repeated until the desired peptide sequence is obtained, followed by detachment of the
peptide from the resin.
2.2 Materials
Peptide materials: Fmoc-L-Val-Wang resin, Fmoc-L-Asp-OH, Fmoc-L-leu-OH,
Fmoc-8-amino-3,6-dioxaoctanoic acid (Fmoc-ADA-OH), 1-[Bis(dimethylamino)methylene]1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid hexafluorophosphate (HATU),
Hydroxybenzotriazole (HOBt), (benzotriazol-1-yl-oxytripyrrolidinophosphonium
hexafluorophosphate (PyBOP), N,N-Diisopropylethylamine (DIPEA), N,N′Diisopropylcarbodiimide (DIC) were purchased from Chem-Impex International, Inc (IL,
USA). Solvents used were of HPLC grade, dichloromethane (DCM), Dimethylformamide
(DMF) and acetonitrile were purchased from fisherscientific (PA, USA). Piperidine,
trifluoroacetic acid (TFA), Triisopropyl silane (TIS) and stearic acid were obtained from
Acros organics (NJ, USA) and used as supplied.
2.3 Method
2.3.1

Design of PAs and calculation of HLB values. Three PAs were designed

with varying lengths of hydrophilic linker units: C16-(PEG2)2-LDV, C16-(PEG2)4-LDV,
C16-(PEG2)6-LDV (Table 2.1). To predict surfactant properties of PAs, the HLB values for
each PA was calculated using the Davies method (Table 2.2) [42]. This method was chosen
since it is useful for calculating HLB values of ionic surfactants. The carboxylic acid groups
of PAs are ionized at physiological pH 7.4 and thus the overall net charge of -1 makes the PA
an anionic structure. This method takes into account the hydrophilicity and hydrophobicity
of chemical groups using a parameter group number. Each chemical group is assigned a
group number, which can be used to calculate the HLB value using equation 2. For all PAs,
carboxylic acid groups present in the peptide and oxygen present in the ethylene oxide linker
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are hydrophilic groups and carbon-hydrogen groups present in the C16 fatty acid chains are
hydrophobic groups.

Equation 2:
𝑯𝑳𝑩 = 𝟕 + +(𝒉𝒚𝒅𝒓𝒐𝒑𝒉𝒊𝒍𝒊𝒄 𝒈𝒓𝒐𝒖𝒑 𝒏𝒖𝒎𝒃𝒆𝒓𝒔) + +(𝒉𝒚𝒅𝒓𝒐𝒑𝒉𝒐𝒃𝒊𝒄 𝒈𝒓𝒐𝒖𝒑 𝒏𝒖𝒎𝒃𝒆𝒓𝒔)

2.3.2

Solid Phase Peptide Synthesis of peptide amphiphiles. PAs were

synthesized using standard Fmoc-chemistry in a polypropylene vessel on a peptide synthesis
shaker. Briefly, wang resin preloaded with valine (Fmoc-L-Val-WR) was soaked in DMF for
30 minutes to swell the resin. Next, the protecting group Fmoc was removed from the amino
group of L-valine by incubating with 20% piperidine in DMF for 30 minutes. The resin was
then washed with DMF and DCM three times each. Following deprotection, Fmoc-L-AspOH was coupled to valine at a molar ratio of 3 by treating with DIC and HOBT in DMF for 3
hours. The same deprotection-coupling steps were used for the coupling of Fmoc-L-leu-OH.
Next, two, four or six Fmoc-ADA-OH (PEG2) linker units were coupled to L-leucine by
treating with HATU, HOBT and DIPEA in DMF for 3 hours. For conjugation of palmitic
acid, the Fmoc group was removed from the final PEG2 linker unit using 20% piperidine in
DMF and the resin was washed using the same procedure as described above. The resin was
then treated with a mixture of PyBOP and DIPEA in DMF:DCM (50:50) for 3 hours. The
resin was then washed and the PA was cleaved from the resin by adding a mixture of
TFA:TIS:H20 (95:2.5:2.5) for 3 hours. The mixture was removed from the peptide synthesis
vessel and TFA was evaporated using nitrogen gas until <0.2 ml of solution was remaining.
Cold isopropyl ether was added to precipitate out the crude PA, which was separated from
isopropyl ether using centrifugation at 3000 rpm. Crude PAs were then suspended in DI
water, lyophilized and subsequently purified by reverse phase High Performance Liquid
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Chromatography (RP-HPLC) using an Agilent 1200 HPLC system equipped with a diode
array detector (DAD). Samples were dissolved in methanol and loaded onto a zorbax agilent
C-18 column (4.6 x 150mm, 5µm) equilibrated with 90% eluent A (0.1% TFA in water) and
10% eluent B (0.1% TFA in acetonitrile) for 30 minutes. PAs were eluted using a linear
gradient method of 10 to 95% eluent B in 20 minutes at 1.0 mL/min. The eluate was
monitored at 280 nm. The PAs were then re-lyophilized for 48 hours and the lyophilized
powders were stored at -80°C. The identity of PAs was confirmed by ESI-MS (Electro Spray
Ionization Mass Spectrometry).
2.4 Results and Discussion
The results show that all PAs have HLB values ranging between 36.55 and 37.45,
which is within the HLB scale for ionic surfactants (table 2.3). The results also show that as
the number of PEG2 units increases, the HLB value increases. PAs with two, four and six
PEG2 linkers were chosen for synthesis and characterization as they are within the HLB scale
and have high HLB values that may improve the aqueous solubility of PAs without PEG2
linkers. Mass Spectrometry confirmed the formation of all PAs. The spectrum displayed the
protonated molecular ion peak [M+H]+ at m/z 874.57 for C16-(PEG2)2-LDV (Figure 2.3).
For C16-(PEG2)4-LDV, the major peak is shown at 1186.6 m/z corresponding to the sodiated
molecule [M+Na]+. Similarly, the peak at 605 Da is representative of the doubly charged
sodiated PA [M+2Na]2+ (figure 2.4). The presence of C16-(PEG2)6-LDV was confirmed by
doubly charged protonated molecular ion peak [M+H]2+ at 728.1 m/z and a doubly charged
protonated sodiated ion [M+H+Na]+2 at 739 m/z (figure 2.5). HPLC purity of all PAs were
>95%. PAs were further characterized for self-assembly into micelles and incorporation into
liposomes and SLNs.
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Figure 2.1: Chemical structure of LDV- peptide amphiphile
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Table 2.2: HLB numbers for chemical groups using the Davies and Rideal method [42]
Hydrophilic groups

Lipophilic groups

Chemical group

Group number

Chemical group

Group Number

-SO4Na+

38.7

-CH2

0.475

-COO-H+

21.2

-CH3

0.475

-COO-Na+

19.1

-CH

0.474

-N (tertiary amine)

9.4

-O-

1.3

Table 2.3: HLB values for peptide amphiphiles
Peptide Amphiphile

HLB value

C16-(PEG2) -LDV

37.5

C16-(PEG2) -LDV

37.95

C16-(PEG2) -LDV

38.45

2

4

6
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STEP 1
Swelling of solid phase resin pre-loaded with
C terminal amino acid Fmoc-L-Valine

STEP 2
Fmoc deprotection
Coupling of amino acids L-aspartic acid and Lleucine

Fmoc-deprotection with 20% piperidine in DMF
Coupling with DIC/HOBT in DMF

STEP 3
Fmoc deprotection
Coupling of PEG2 linkers

Fmoc-deprotection with 20% piperisine in DMF
Coupling with HATU/HOBT/DIPEA in DMF

STEP 4
Coupling of palmitic acid

Coupling with PyBOP/DIPEA in DMF/DCM

STEP 5
Peptide Cleavage from resin

STEP 6
Lyophilization

Cleavage cocktail: TFA:TIS:H20

STEP 7
Identification by Mass Spectrometry (MS)

STEP 8
Purification by HPLC

Figure 2.2: Flow chart for solid phase peptide synthesis steps and LDV peptide
amphiphile characterization
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Figure 2.3: ESI-MS spectrum of C16-(PEG2)2-LDV peptide amphiphile
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Figure 2.4: ESI-MS spectrum of C16-(PEG2)4-LDV peptide amphiphile
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Figure 2.5: ESI-MS spectrum of C16-(PEG2)6-LDV peptide amphiphile
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Chapter 3: Design and Preparation of LDV-targeted Nanocarriers
3.1 Introduction
A major challenge associated with nanotechnology for cancer therapy is
the retention of drug inside nanocarriers following intravenous administration, as drug should
remain inside or complexed to the nanocarrier until it reaches the target cancer cells. The
most extensively studied nanocarriers are micelles and liposomes and the stability of these
systems is a critical factor for effective drug delivery. Micelles are attractive drug delivery
vehicles and have several advantages such as small size for exploiting the EPR effect,
hydrophobic core for loading of poorly soluble anti-cancer agents and hydrophilic shell for
stability resulting in long circulation kinetics. The chemical composition and molecular
weight of the amphiphiles can also be adjusted to achieve effective drug release behavior,
physical stability and drug loading [43]. However, poor stability is a significant challenge
that hampers the clinical translation of micelles. Specifically, micelles are dynamic systems
and dilution upon intravenous administration can reduce surfactant concentrations below the
CMC, resulting in premature drug release before reaching the target tumor site. Micelles are
also prone to dissociation through interactions with blood components such as albumin and
apolipoproteins. Compared to micelles, liposomes have several advantages: they are able to
encapsulate both hydrophilic and hydrophobic drugs and they are mechanically stronger
making them less prone to breakage and dissociation upon dilution [44]. However, the use of
liposomes is also limited by disadvantages such as drug leakage from the bilayer membrane,
poor physical stability, low encapsulation efficiency, short shelf-life and destabilization
through interactions with serum proteins. Compared to liposomes and micelles, SLNs have
the potential to provide better control over drug release and drug delivery since the lipid
components are solid at both room and body temperature. This enables improved retention of
drug molecules inside the nanocarrier, reduced leakage of drug molecules and prolonged
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release of drug molecules in vivo. SLNs also have good physical stability and good in vitro
release characteristics. However, SLNs also have several disadvantages including
unpredictable gelation tendency, polymorphic transitioning and low drug loading efficiency
[45]. Therefore, there is a necessity to develop nanocarriers that are better able to retain the
drug before reaching the target site, are resistant to disruption from interactions with serum
proteins and therefore offer better control over drug release and drug delivery. To develop
nanocarriers with optimum physicochemical characteristics, the size, charge and morphology
can be determined to help understand or predict the in vivo behavior of nanocarriers. For
determination of size, Transmission Electron Microscopy (TEM) and Dynamic Light
Scattering (DLS) are commonly used. DLS measures the hydrodynamic diameter of
nanocarriers dispersed in aqueous solution and this method is widely preferred due to the
non-invasive fast measurement times and size determination of nanocarriers in its native
colloidal state. This method typically relies on Rayleigh Scattering from the nanoparticles in
solution that are undergoing Brownian motion [46]. This is the random movement of
particles in a liquid that occurs as a result of the continuous bombardment from solvent
molecules of the surrounding medium. In general, larger particles move more slowly in
solution compared to smaller particles and the velocity of brownian motion is defined the
translational diffusion coefficient. Therefore, the size of the nanocarrier refers to how the
particle diffuses within the solution and can be calculated from the translation diffusion
coefficient using the Stokes-Einstein equation [46, 47]:

Equation 3.1:

AB

𝑑 (𝐻) = CDEF

Where d(H) is the hydrodynamic diameter, D is the translational diffusion coefficient, k is the
Boltzmann’s constant, T is the absolute temperature and η is the viscosity. Despite frequent
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use of this method, DLS has several limitations such as poor resolution of particle sizes and
the inability to determine nanocarrier morphology, porosity and all particle populations
present in a polydisperse sample. In contrast, TEM helps to overcome these disadvantages
by direct observation of samples, which allows for morphology characterization as well as
size determination. The morphology of nanocarriers is a characteristic that has been shown
to dictate the efficacy of targeting and cellular uptake. It was shown that antibody coated
rod-shaped nanoparticles compared to spherical were more effective at targeting endothelial
cells due to the large surface area and thus increased interactions of antibody binding sites to
cell membrane receptors [28]. For size and morphology characterization, nanocarrier
samples are adsorbed onto a support film, followed by negative staining to view dehydrated
structures under an electron beam. Negative staining can be achieved by applying heavy
metals salts to the sample, where the hydrated regions in and around the particle become
occupied. As the stain is dried, an amorphous electron-dense replica of the particle is
formed. Upon imaging, the electron beam primarily interacts with the stain, enhancing the
contrast of the image, where the image is light in areas occupied by the nanocarrier and dark
in areas surrounding the nanocarrier. Despite the usefulness of this method, sample
preparation is expensive, time consuming and requires drying of nanocarriers. This can cause
the sample to shrink, break down or agglomerate, producing a sample image that is no longer
representative of the native colloidal state [48]. In addition to size and morphology, the
charge or zeta potential is a fundamental parameter that dictates nanocarrier behavior such as
aggregation, interaction with cell membranes and other surfaces such as serum proteins [49].
The zeta potential is defined as the difference in the electrical potential on the shear surface
of the nanocarrier and the electrical potential of the solution and is determined by an
electrophoresis experiment that measures the velocity of the nanocarriers using Laser
Doppler Velocimetry (LDV). This is followed by application of the Henry equation to
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calculate the zeta potential (Equation 3.2), where z is the zeta potential, U is the
electrophoretic mobility, 𝜀 is the dielectric constant, η is the viscosity and f(ka) is Henry’s
function [47]. Positively charged or neutral nanocarriers will be preferentially taken up by the
negatively charged membrane, although cationic lipids and polymers are known to be toxic to
cells.

Equation 3.2:

𝑈=

IJ K L (AM)
CE

PAs were assessed for their ability to self-assemble into micelles. At low surfactant
concentrations, surfactant molecules exist as monomers and adsorb at the liquid surface. As
the concentration of surfactant increases, the surface tension of the solution decreases and the
surface becomes saturated with surfactant molecules. Upon further addition of surfactant,
surfactant monomers start to self-assemble into micelles and the concentration at which this
occurs is known as the Critical Micelle Concentration (CMC). PAs were predicted to have
amphiphilic properties from calculated HLB values and so it was hypothesized that these PAs
would self-assemble into micelles, where the fatty acid chains aggregate away from the
aqueous solution to form a hydrophobic core and the LDV-PEG2 region faces the aqueous
solution forming a hydrophilic corona (figure 3.1). The CMC can be determined by
determining the concentration at which an inflection point occurs when physicochemical
properties such as surface tension are plotted as a function of concentration. Light scattering
methods can also be used, where a sharp increase in turbidity is observed. A commonly used
method for CMC determination is known as the fluorescence probe technique. Here, a
hydrophobic fluorescent dye known as pyrene, demonstrates sensitivity to the polarity of the
surrounding medium and consequent changes in spectral properties [50]. Below the CMC,
pyrene is solubilized in water and above the CMC, when micelles are forming, pyrene
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partitions into the hydrophobic core. As a result, the pyrene emission spectrum exhibits
changes in fluorescent intensity and vibrational structure of emission spectrum. Specifically,
there are 5 vibrionic bands. The intensity of the third (383 nm) vibrionic band is significantly
enhanced in a hydrophobic environment and the intensity of the first peak is increased in a
polar environment (figure 3.7). Therefore, the ratio of the 3rd and 1st peak intensities in the
emission spectrum provides a measure of the apparent polarity of the environment. An
increase in this ratio, indicates a decrease in polar environment of the pyrene. The CMC can
be determined from the inflection points of pyrene intensity ratio and surfactant concentration
plots.

Figure 3.1: Schematic representation of the structure and formation of micelles from LDVpeptide amphiphiles in aqueous solution.
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To compare the stability of liposomes with micelles, the lipid compositions must be a
similar as possible. Micelles are formed from single chain amphiphiles, due to steric effects
of the hydrocarbon chain and steric conditions determined by the charged head group. In
contrast, double-chained amphiphiles favor the formation of bilayers, due to the steric
restriction associated with the second hydrocarbon chain [51]. For micelle formation, single
chain palmitic acid was conjugated with peptide-linker segments to confer amphiphilic
properties. To form liposomes of similar composition to these micelles, palmitic acid derived
double-chain amphiphilic phospholipids can be used, ensuring that the fatty acid chain length
of micelles and liposomes are kept the same. Based on this rationale, a synthetic phospholipid
named dipalmitoylphosphatidylcholine (DPPC) was selected for liposome formation since it
is composed of two palmitic acid fatty acid chains attached to a phosphatidylcholine headgroup, enabling the formation of a phospholipid bilayer. To impart similar head group
properties, PAs were incorporated into DPPC liposomes. It was hypothesized that the
palmitic fatty acid chain of PAs would insert into the DPPC bilayer, facilitating the anchoring
of the hydrophilic (PEG2)n-LDV head group to the liposome surface (figure 3.2). The two
most common methods to produce liposomes are sonication and extrusion, where each
method produces different mean sizes and size distributions. Thin lipid films or lipid cakes
are hydrated in aqueous medium and stacks of crystalline bilayers become fluid and swell.
The hydrated lipid sheets detach during agitation and self-close to form MLVs, which are
heterogenous in size and number of lamellae and range between a few hundred nanometers to
several microns. MLVs are concentric bilayers separated by narrow aqueous spaces and can
be downsized to SUVs ranging between 20 nm to 100 nm by energy input in the form of
sonic energy or mechanical energy. For sonication, acoustic energy is applied to lipid
suspensions from a bath or probe tip sonicator. Smaller sized liposomes can be produced by
increasing the sonication time and this process is relatively fast. For application of
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mechanical energy to produce liposomes, a lipid suspension is passed through a
polycarbonate membrane with a specific pore size, and this results in vesicle sizes close to
the diameter of the pore size. Compared to sonication, this process is slower but produces
reproducible sizes and size distributions [52].
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Figure 3.2: Schematic representation of the structure and formation of liposomes from LDVpeptide amphiphiles and DPPC lipids in aqueous solution using the thin-film hydration
method
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To design SLNs of similar composition to micelles and liposomes, a palmitic acid
derived solid lipid was used to form the hydrophobic solid core component. Tripalmitin is a
triglyceride obtained by acylation of three hydroxy groups of glycerol by palmitic acid
(C16:0/C16:0/C16:0). The high melting point of tripalmitin (66⁰C to 68⁰C) means that at
room temperature and physiological body temperature, tripalmitin is solid, which may
significantly reduce the mobility of drug molecules within the lipid core, preventing
premature drug release. To stabilize the solid lipid core and impart targeting properties, PAs
were incorporated (figure 3.3). SLNs can be prepared via a variety of methods including
high pressure homogenization (HPH), solvent emulsification/evaporation, supercritical fluid
technology, ultrasonication or high-speed homogenization. Many of these methods after
often characterized by poorly controlled conditions, which lead to poly-disperse sizes and
size distributions. Microfluidic technology has been shown to overcome these disadvantages
by providing better control of particle sizes and stability of lipid nanoparticles through
optimization of parameters such as the Flow Rate Ratio (FRR), the total flow rate (TFR),
choice of solvents, temperature and microfluidic chip design [53-60]. A typical microfluidic
micro-mixer contains a microfluidic cartridge comprising of moulded channels with
staggered herringbone structures. The microfluidic chips are designed to have two inlet
channels that merge into a microchannel, where one channel is used to pump lipid mixtures
in ethanol and the second channel is used to pump aqueous solutions. SLNs are formed when
these two phases mix through staggered herringbone microchannels, in which chaotic flow
occurs subjecting the fluid to a repetitive series of a rotational flow profile. This design
increases the rate of mixing because the grooves cause the streams of fluid to twist over each
other, allowing rapid and controlled mixing of both phases. During mixing, when a specific
ethanol concentration is reached, lipids precipitate and start to grow and form nanoparticles
(figure 3.3).
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Figure 3.3: Schematic representation of the structure and formation of solid lipid
nanoparticles from LDV peptide amphiphiles and tripalmitin lipid in aqueous solution, using
microfluidic technology.
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3.2 Materials
PAs were synthesized as described in section 2. DPPC lipids and liposome extruder
was purchased from Avanti polar lipids (AL, USA). Tripalmitin and pyrene was purchased
from Sigma-Aldrich (MO, USA). Solvents including DCM, methanol, ethanol and
chloroform were purchased from fisherscientific (Pittsburg, PA). Copper formvar 200 mesh
grids were purchased from Ted Pella Inc (Redding, CA)
3.3 Methods
3.3.1

Liposome preparation. Liposomes were formed by thin-film hydration. A

mixture of DPPC and PA were dissolved in chloroform: methanol = 2:1 (v/v) at a molar ratio
of 1:0.05. Organic solvents were evaporated to dryness under a stream of nitrogen gas and
solvent traces were removed by leaving the glass tubes under vacuum overnight. The dried
lipid film was then hydrated by the addition of DI water at a temperature between 50⁰C to
55⁰C, followed by vortexing periodically for 30 minutes to detach any lipid from the glass
surface. Hydration was carried out in a water bath and the temperature was maintained above
the main phase transition temperature (Tm) of lipids (41⁰C for DPPC). This process resulted
in the formation of MLVs, which were subjected to six freeze-thaw cycles with liquid
nitrogen and heated DI water. MLVs were downsized by extruding 21 times through 0.1µmpore polycarbonate filters to produce SUVs. Liposomes were prepared for each PA (C16(PEG2)2-LDV, C16-(PEG2)4-LDV, C16-(PEG2)6-LDV) and each liposome composition was
prepared in triplicates.
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3.3.2

Solid lipid nanoparticle preparation. The NanoAsssmblr (Benchtop,

Precision NanoSystems Inc., Vancouver, Canada) was used to prepare SLNs by microfluidic
mixing. Specifically, a microfluidic cartridge comprising of moulded channels with
staggered herringbone structures was used to formulate SLNs by mixing of the organic
(tripalmitin in ethanol) and aqueous (PA in water) phases at a molar ratio of 1:0.5. The
organic and aqueous phases were pumped into two inlets of the microfluidic chip using
disposable syringes and mixing was controlled by setting the FRR to 3:1 and the TFR to 15
mL/min. At all steps of preparation, the organic and aqueous phases were kept at 75⁰C by
keeping solutions in the oven and installing a heat block into the NanoAssemblr instrument.
Next, the mixture was collected from the NanoAssemblr and transferred into a G2 slide-ALyzer dialysis cassette (MWCO 10,000) and dialyzed against DI water to remove traces of
ethanol. Specifically, the dialysis membrane was hydrated in DI water for 2 minutes prior to
insertion of SLN sample. The dialysis cassette was stirred in DI water, which was exchanged
every hour for 3 hours. Post-dialysis, the sample was removed from the dialysis cassette and
used for further characterization. SLNs were prepared for each PA (C16-(PEG2)2-LDV, C16(PEG2)4-LDV, C16-(PEG2)6-LDV) and all SLN compositions were prepared in triplicate.
3.3.3

Characterization of micelles, liposomes and solid lipid nanoparticles.

a) Determination of the critical micelle concentration (CMC). The CMC was
determined using the pyrene fluorescence method. Stock solutions of PA were prepared in
methanol at 2 mg/mL and calculated volumes of the stock solutions were added to glass
scintillation vials. Next, a stock solution of pyrene in dichloromethane was prepared at
0.6µM and 50µl of this solution was added to each vial. The mixture was vortexed to ensure
a homogenous solution of PAs and pyrene. Organic solvents were evaporated under a stream
of nitrogen gas and left under a fume hood overnight to form a thin film of PA and pyrene.
The dry films were then hydrated with DI water to achieve PA concentrations ranging
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between 0.01µM to 100µM. Samples were equilibrated in a water bath at 37⁰C and shaken at
85 rpm. Following equilibration, the fluorescence spectra was recorded using a
spectrofluorometer (Shimadzu Spectrofluorometer RF-5301 PC Shimadzu corporation,
Pleasanton, USA). Samples were measured at an excitation wavelength of 337 nm and an
emission wavelength range of 350 nm and 500 nm. The first (I1) 373 nm and third (I3) 383
nm vibrionic emission peak fluorescence intensities were recorded and the ratio of the third
and first vibrionic emission peak fluorescence intensities was plotted against log
concentration of PAs. This method was carried out for all three PAs (C16-(PEG2)2-LDV,
C16-(PEG2)4-LDV, C16-(PEG2)6-LDV) and all experiments were performed in triplicate.
b) Size, PDI and charge characterization of micelles, liposomes and SLNs. The
size, PDI and zeta potential of blank liposomes and blank SLNs were determined using DLS
on the Zetasizer ZS 90 (Malvern Instruments, Ltd., Malvern, UK). For nanocarrier size and
PDI, measurements were taken in a disposable microcuvette at 25°C. For zeta potential,
samples were diluted in DI water and inserted into a disposable folded capillary zeta cell
using a syringe. For each sample, measurements were taken three times using the auto run
setting. The morphology and size of blank micelles was determined using TEM on a Philips
CM120 BioTwin. Micelles were prepared from PAs as described above. A drop of each
micelle solution was placed onto a formvar 200-mesh copper grid coated with carbon and left
to dry in open air. Next, the sample was stained using a drop of 2% w/v phosphotungstic acid
(pH 3) to enhance the contrast of the sample and excess solution was removed using filter
paper. After air-drying, the copper grid was transferred onto the microscope sample holder
for imaging.
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3.4 Results and Discussion
The formation of micelles is a thermodynamic process and is driven by the increase in
entropy when hydrophobic regions of the amphiphile are removed form water and aggregate
to form a hydrophobic core. This hydrophobic effect decreases the ordered structure of the
water molecules that surround the micelle structure, to attain a minimum free energy state.
Micelles are formed at the CMC, which is characterized by an inflection point when
physicochemical properties such as surface tension undergo sharp changes at a specific
surfactant concentration. Factors that influence micellization include, the structure and
length of the hydrophobic and hydrophilic regions, electrolyte addition and temperature. In
general, an increase in length of the hydrocarbon chain results in an increase in micelle size
and a decrease in the CMC. An increase in hydrophilic head group length (ethylene oxide
chain length) renders micelles more hydrophilic with higher CMC values. In this study, the
CMC was determined at 37⁰C in water using the pyrene fluorescence probe method and all
three PAs formed micelles with a CMC ranging between 23.7µM to 38.8µM (table 3.1 and
figures 3.4 to 3.6) which are typical values for low molecular weight surfactants. Micelles
with the largest number of PEG2 linker units (C16-(PEG2)6-LDV) had the largest CMC
values. This can be explained by the fact that micelle formation is a result of a balance of
intermolecular forces, where attractive forces occur through hydrophobic interactions
between hydrophobic fatty acid chains and repulsive forces arise from steric or electrostatic
interactions between the polar PEG2-LDV head groups [61, 62]. As the number of PEG2
units increases, the repulsive interactions are larger compared to the hydrophobic interactions
and thus larger concentrations of PAs are needed to form micelles [63, 64]. In contrast,
micelles with lower CMC values (C16-(PEG2)2-LDV, C16-(PEG2)4-LDV) are more resistant
to dissociation upon dilution. The size of micelles was not determined by DLS and this is
likely due to the dynamic nature of micelles and difficulty in determining micelle size in the
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presence of two populations (micelle aggregates and monomers). Therefore, direct
observation of micelles by TEM showed that all blank micelles were spherical in morphology
and sizes ranged between 55 nm to 295 nm, where C16-(PEG2)6-LDV micelles had the
largest sizes (figure 3.8). This is likely due to the longer number of ethylene oxide units and
subsequent increased repulsive forces resulting in a looser packing density, forming larger
micelle structures [65]. Conversely, hydrophobic interactions of micelles with shorter
hydrophilic head groups predominated, resulting in tighter packing of hydrophobic fatty acid
chains, forming smaller micelles. The size of blank liposomes was in the range of 92.51 ±
0.29 nm to 102.73 ± 0.12 nm and the size of SLNs were smaller in the range of 78.46 ± 4.31
nm to 86.93 ± 3.49 nm (table 3.2). These results indicate that the sizes of blank micelles,
liposomes and SLNs are in the ideal range for tumor targeting via the EPR effect. The PDI
values for liposomes and SLNs were ≤2, which indicates a narrow size distribution.
The magnitude of the zeta potential provides an indication of the colloidal stability.
Specifically, zeta potential values more positive than +30 mV or more negative than -30 mV
will repel each other decreasing the tendency to flocculate, indicating good colloidal stability.
For liposomes, the zeta potential values were negative ranging between -34.47 ± 0.25 mV
and -39.47 ±1.33 mV. The zeta potential values for SLNs ranged between -45.46 ± 19.90
mV and -65.55 ± 8.36 mV. The negative zeta potential values can be attributed to the
charged carboxylate group of aspartic acid in the LDV peptide region, indicating good
colloidal stability.
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Figure 3.4: Critical micelle concentration plot of I3/I1 ratio of pyrene v/s concentration of
C16-(PEG2)2-LDV peptide amphiphiles (n=3)
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Figure 3.5: Critical micelle concentration plot of I3/I1 ratio of pyrene v/s concentration of
C16-(PEG2)4-LDV peptide amphiphiles (n=3)
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Figure 3.6: Critical micelle concentration plot of I3/I1 ratio of pyrene v/s concentration of
C16-(PEG2)6-LDV peptide amphiphiles (n=3)
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Figure 3.7: Fluorescence spectra of pyrene for LDV-targeted micelles loaded with pyrene
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Table 3.1: Critical micelle concentration values for LDV-targeted micelles (n=3)
Peptide Amphiphile

CMC (μM)

C16-(PEG2)2-LDV

28.31 ± 3.85

C16-(PEG2)4-LDV

23.68 ± 0.72

C16-(PEG2)6-LDV

38.76 ± 2.27
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Figure 3.8: Transmission Electron Microscope images of LDV-targeted blank micelles
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Table 3.2: Comparison of size, zeta potential and PDI of LDV-targeted blank micelles, blank
liposomes and blank solid lipid nanoparticles (n=3)

Nanocarrier

Size (nm)

Zeta potential (mV)

PDI

C16-(PEG2)2-LDV micelle

54 ± 4.90

ND

ND

C16-(PEG2)4-LDV micelle

55 ± 10.0

ND

ND

C16-(PEG2)6-LDV micelle

295 ± 65.0

ND

ND

C16-(PEG2)2-LDV liposome

97.32 ± 0.45

-39.47 ± 1.33

0.200

C16-(PEG2)4-LDV liposome

92.51 ± 0.29

-34.47 ± 0.25

0.174

C16-(PEG2)6-LDV liposome

102.73 ± 0.12

-35.33 ± 0.10

0.137

C16-(PEG2)2-LDV SLN

78.46 ± 4.31

-45.46 ± 19.90

0.209 ± 0.004

C16-(PEG2)4-LDV SLN

87.07 ± 1.79

-65.55 ± 8.363

0.207 ± 0.002

C16-(PEG2)6-LDV SLN

86.93 ± 3.49

-61.92 ± 3.078

0.186 ± 0.010
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Chapter 4: In Vitro Stability and Drug Release Characterization
4.1 Stability of LDV-targeted Micelles, Liposomes and SLNs by FRET
4.1.1

Introduction. One of the major challenges with the use of nanocarriers, is

their instability when administered systemically. For example, micelles are known to
disassemble when diluted below the CMC upon systemic administration. Additionally,
nanocarriers can destabilize and disrupt due to interactions with blood components, causing
premature drug release and reduced anti-cancer efficacy. Nanocarriers can be loaded with
fluorescent dyes that are used to probe the stability upon dilution and under physiological
conditions. For example, Forster Resonance Energy Transfer (FRET) is a distance-dependent
process where energy is transferred from an excited fluorophore (donor dye) to another
fluorophore (acceptor dye) and has been used to probe the stability of various nanocarriers
including polymeric micelles and liposomes [66, 67]. Specifically, donor and acceptor FRET
dyes (DiO and Dil) can be loaded into the hydrophobic core of micelles, the bilayer of
liposomes and the solid lipid core of SLNs. Upon excitation of the donor dye, energy is
transferred to the acceptor dye and energy is released at the emission wavelength of the
acceptor molecules, due to the close proximity of the dyes within the hydrophobic regions of
the nanocarriers. Typically, energy transfer can only occur if the dyes are within 10
angstroms of each other. When nanocarriers are disrupted, the dyes are released and the
larger distance between them results in a loss of energy transfer between donor and acceptor
dyes. High FRET efficiencies indicate the presence of physically stable nanocarriers and low
FRET efficiencies indicate poor physical stability of nanocarriers.
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Figure 4.1: Schematic representation of intact and disrupted FRET dye-loaded micelles

Figure 4.2: Schematic representation of intact and disrupted FRET dye-loaded
liposomes
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Figure 4.3: Schematic representation of intact and disrupted FRET dye-loaded solid
lipid nanoparticles
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4.1.2

Materials. PAs were synthesized as described in the section 2. (CA, USA).

DPPC lipids and liposome extruder was purchased from Avanti polar lipids (AL, USA).
Tripalmitin was purchased from Sigma-Aldrich (MO, USA). FRET dyes 3,3′dioctadecyloxacarbocyanine perchlorate (DiO) and 1,1′-dioctadecyl-3,3,3′,3′tetramethylindocarbocyanine perchlorate (Dil) were purchased from Invitrogen (Carlsbad
CA, USA). Dialysis membranes MWCO 1000 Da were purchased from Spectrum
Laboratories (Rancho Dominguez, CA, USA), Solvents including DCM, methanol, ethanol,
N,N’-dimethyl formamide (DMF) and chloroform were purchased from fisherscientific
(Pittsburg, PA).
4.1.3

Methods. FRET dyes DiO and Dil were loaded into micelles, liposomes and

SLNs using the same methods for preparation of blank nanocarriers. Table 4.1 summarizes
the methods, compositions, lipid concentrations and drug loading of FRET dye-loaded
nanocarriers.
a) Preparation of FRET dye-loaded micelles. FRET pair dyes DiO and Dil
were loaded into micelles through the dialysis membrane technique. PAs were mixed
together with FRET dyes in DMF and left shaking in a water-bath at 50⁰C for approximately
1 hour. The mixture was then transferred into dialysis membrane tubing (MWCO 1000) and
dialyzed against 1 liter of water, which was exchanged three times over 24 hours. After
dialysis, micelle samples were removed by transferring into glass vials and covering with
aluminum foil prior to characterization. Micelles were prepared from all three PAs and each
micelle composition was prepared in triplicates.
b) Preparation of FRET dye-loaded liposomes. Liposomes were prepared using the
thin-film hydration and extrusion method. A mixture of DPPC, PA and FRET dyes were
dissolved in chloroform: methanol = 2:1 (v/v) at a molar ratio of 1:0.5:0.02. Organic solvents
were evaporated to dryness under a stream of nitrogen gas and solvent traces were removed
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by leaving the glass tubes under vacuum overnight. The dried lipid film was then hydrated
by the addition of aqueous solution at a temperature between 50⁰C to 55⁰C, followed by
vortexing periodically for 30 minutes to detach any lipid from the glass surface. Hydration
was carried out in a water bath and the temperature was maintained above the main phase
transition temperature (Tm) of lipids (41⁰C for DPPC). This process resulted in the formation
of MLVs, which were subjected to six freeze-thaw cycles with liquid nitrogen and heated DI
water. MLVs were downsized by extruding 21 times through 0.1µm-pore polycarbonate
membrane filters. Liposomes were prepared using all three PAs and each liposome
composition was prepared in triplicates. Following preparation, liposome suspensions were
protected with aluminum foil prior to characterization.
c) Preparation of FRET dye-loaded solid lipid nanoparticles. The NanoAssemblr
(Benchtop, Precision NanoSystems Inc., Vancouver, Canada) was used to prepare SLNs by
microfluidic mixing. Specifically, a microfluidic cartridge comprising of moulded channels
with staggered herringbone structures was used to formulate SLNs by mixing of the organic
(tripalmitin and FRET dyes in ethanol) and aqueous (PA in water) phases at a molar ratio of
1:0.5:0.02. The organic and aqueous phases were pumped into two inlets of the microfluidic
chip using disposable syringes and mixing was controlled by setting the FRR to 3:1 and the
TFR to 15mL/min. At all steps of preparation, the organic and aqueous phases were kept at
75⁰C by keeping solutions in the oven and installing a heat block into the NanoAssemblr
instrument. Next, the mixture was collected from the NanoAssemblr and transferred into G2
slide-A-Lyzer dialysis cassettes (MWCO 10,000) and dialyzed against DI water to remove
traces of ethanol. Specifically, the dialysis membrane was hydrated in DI water for 2 minutes
prior to dialysis. Then the dialysis cassette was stirred in DI water, which was exchanged
every hour for 3 hours. Post-dialysis, the sample was removed from the dialysis cassette and
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used for further characterization. SLNs were prepared using all three PAs and all SLN
compositions were prepared in triplicate.
d) Stability characterization. The dilution stability of micelles, liposomes
and SLNs was determined by diluting 10-fold in aqueous solution or methanol (control) and
recording the fluorescence spectra (excitation 484 nm, emission 495 nm to 600 nm) using a
fluorescence spectrophotometer (Shimadzu Spectrofluorometer for micelles and liposomes
and a SpectraMax M2 microplate reader for SLNs). FRET ratios were calculated using
fluorescence intensity values of dyes; IDIL/(IDIL+IDIO), where lower ratios represent increased
micelle, liposome or SLN disassembly. For stability in serum, micelles, liposomes and SLNs
were diluted 10-fold in human serum or in 0.1% triton X-100 (control) and the FRET ratios
were calculated using the same method. The results were plotted using GraphPad Prism
software and a non-linear fit of FRET ratio’s was generated by least squares and the rate
constants (K) were determined. The rate constants were statistically compared using oneway ANOVA followed by Tukey post-test. A p value <0.05 was considered statistically
significant.
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4.1.4 Results and discussion. The effectiveness of nanocarriers for tumor targeting
is dependent on the ability to remain intact before reaching the target tumor site. Therefore,
nanocarriers must remain intact and circulate in the blood for a sufficient amount of time to
allow accumulation at the tumor site. Specifically, premature drug release can occur when
micelles are administered intravenously and diluted below the CMC. Furthermore,
nanocarriers are prone to protein adsorption, leading to opsonization and phagocytosis by
macrophages of the RES in the blood circulation or in the liver and spleen. Serum proteins
can also partition into the nanocarriers, causing disruption and premature drug release.
Therefore, for effective drug targeting and delivery to occur, nanocarriers must be able to
withstand the effects of dilution and remain stable in the presence of serum. FRET dyes were
loaded into micelles, liposomes and SLNs and these nanocarriers were characterized for their
ability to remain intact upon dilution and in the presence of serum. When micelles,
liposomes and SLNs were diluted in excess aqueous solution, the fluorescence spectrum
remained unchanged, showing a major emission peak at 570 nm upon excitation at the
appropriate wavelength (figures 4.4 to figure 4.24). This indicates energy transfer due to the
close proximity of dyes in the bilayer of liposomes and in the core of micelles and SLNs. For
all nanocarriers except C16-(PEG2)2-LDV micelles, FRET efficiencies remained high
(≥0.85), indicating good stability upon dilution (table 4.2 and table 4.3). When micelles,
liposomes and SLNs were disrupted in methanol, FRET dyes were released and diffused
apart, resulting in loss of energy transfer. As a result, a shift in the emission peak from 570
nm to 505 nm was observed. When micelles, liposomes and SLNs were diluted in human
serum, an increase in the fluorescence intensity at 505 nm and a decrease at 570 nm was
observed over 8 hours, indicating nanocarrier disassembly or FRET dye molecule release
over time (figure 4.25 to figure 4.45). The rate of nanocarrier disassembly was the fastest for
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micelles, followed by liposomes and SLNs, with rate constant values of 2.77 ± 0.39 hr-1, 0.61
± 0.09 hr-1 and 0.20 ± 0.05 hr-1 respectively (table 4.5). Upon statistical analysis of rate
constants, there were significant differences between nanocarriers (p<0.0001). The Tukey
test revealed a significant difference between the rate constants of micelles vs liposomes
(p<0.0001) and micelles vs SLNs (p<0.0001). However, there was no significant difference
between the rate constants of liposomes and SLNs (p=0.16). For micelles in serum, the
FRET efficiency decreased from 1 to 0.51 over 1 hour. At 3 hours, the FRET ratio (≈0.42)
reached a plateau, indicating complete micelle disassembly or FRET molecule release at this
time. For liposomes in serum, the decrease in FRET efficiency over 1 hour was less
compared to micelles (1 to 0.74) and the FRET ratio plateaued at 5 hours (≈0.45). Compared
to micelles and liposomes, SLNs were the most stable in serum with only a small decrease in
the FRET ratio from 1 to 0.88 over 1 hour and a steady decrease to ≈0.63 over 8 hours.
When micelles, liposomes and SLNs were disrupted in triton X-100, a shift in the emission
peak from 570 nm to 505 nm was observed, indicating complete disassembly or FRET
molecule release. Overall, the results demonstrate that micelles were more prone to
destabilization in the presence of serum compared to liposomes and SLNs. Micelles formed
from low molecular weight amphiphiles are dynamic structures and the continuous exchange
of amphiphiles between micelles contributes to poor stability. However, compared to
micelles, the phospholipid bilayer of liposomes imparts increased rigidity and improved
mechanical properties, leading to increased retention of FRET dye molecules and increased
resistance to disruption by serum proteins. SLNs demonstrated higher stability over micelles
and liposomes, which is likely due to rigid solid nature of the lipid core, which affords
increased FRET dye retention and resistance to disruption by serum proteins.
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Figure 4.5: Time resolved emission spectra of Dil + DiO loaded C16-(PEG2)2-LDV micelles
diluted 10-fold in aqueous solution

Figure 4.6: Emission spectra of Dil + DiO C16-(PEG2)2-LDV micelles diluted 10-fold in
methanol
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Figure 4.7: Time resolved emission spectra of Dil + DiO loaded C16-(PEG2)4-LDV micelles
diluted 10-fold in aqueous solution

Figure 4.8: Emission spectra of Dil + DiO C16-(PEG2)4-LDV micelles diluted 10-fold in
methanol
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Figure 4.9: Time resolved emission spectra of Dil + DiO loaded C16-(PEG2)6-LDV micelles
diluted10-fold in aqueous solution

Figure 4.10: Emission spectra of Dil + DiO C16-(PEG2)6-LDV micelles diluted 10-fold in
methanol
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Figure 4.11: Normalized FRET efficiency of LDV-targeted liposomes when diluted 10-fold
in aqueous solution (n=3)
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Figure 4.12: Time resolved emission spectra of Dil + DiO loaded C16-(PEG2)2-LDV
liposomes diluted 10-fold in aqueous solution

Figure 4.13: Emission spectra of Dil + DiO C16-(PEG2)2-LDV liposomes diluted 10-fold
in methanol
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Figure 4.14: Time resolved emission spectra of Dil + DiO loaded C16-(PEG2)4-LDV
liposomes diluted 10-fold in aqueous solution

Figure 4.15: Emission spectra of Dil + DiO C16-(PEG2)4-LDV liposomes diluted 10-fold in
methanol
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Figure 4.16: Time resolved emission spectra of Dil + DiO loaded C16-(PEG2)6-LDV
liposomes diluted 10-fold in aqueous solution

Figure 4.17: Emission spectra of Dil + DiO C16-(PEG2)6-LDV liposomes diluted 10-fold in
methanol.
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Figure 4.18: Normalized FRET efficiency of LDV-targeted solid lipid nanoparticles when
diluted 10-fold in aqueous solution (n=3)
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Figure 4.19: Time resolved emission spectra of Dil + DiO loaded C16-(PEG2)2-LDV solid
lipid nanoparticles diluted 10-fold in aqueous solution

Figure 4.20: Emission spectra of Dil + DiO C16-(PEG2)2-LDV solid lipid nanoparticles
diluted 10-fold in methanol
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Figure 4.21: Time resolved emission spectra of Dil + DiO loaded C16-(PEG2)4-LDV solid
lipid nanoparticles diluted 10-fold in aqueous solution

Figure 4.22: Emission spectra of Dil + DiO C16-(PEG2)4-LDV solid lipid nanoparticles
diluted 10-fold in methanol
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Figure 4.23: Time resolved emission spectra of Dil + DiO loaded C16-(PEG2)6-LDV solid
lipid nanoparticles diluted 10-fold in aqueous solution

Figure 4.24: Emission spectra of Dil + DiO C16-(PEG2)6-LDV solid lipid nanoparticles
diluted 10-fold in methanol
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Table 4.2: Normalized FRET efficiencies of DiO + Dil dye-loaded micelles, liposomes and
solid lipid nanoparticles when diluted 10-fold in aqueous solution (n=3)
Nanocarrier

Average Normalized FRET efficiency
at 1 hour

C16-(PEG2)2-LDV micelles

0.68 ± 0.01

C16-(PEG2)4-LDV micelles

0.88 ± 0.02

C16-(PEG2)6-LDV micelles

0.87 ± 0.02

C16-(PEG2)2-LDV liposomes

0.85 ± 0.01

C16-(PEG2)4-LDV liposomes

0.86 ± 0.00

C16-(PEG2)6-LDV liposomes

0.85 ± 0.01

C16-(PEG2)2-LDV SLNs

0.95 ± 0.01

C16-(PEG2)4-LDV SLNs

0.99 ± 0.00

C16-(PEG2)6-LDV SLNs

0.97 ± 0.00

93

Table 4.3: Average normalized FRET efficiencies of DiO + Dil FRET dye-loaded micelles,
liposomes and solid lipid nanoparticles when diluted 10-fold in aqueous solution (n=3)

Nanocarrier

Average Normalized FRET efficiency at 1 hour

C16-(PEG2)n-LDV micelles

0.81 ± 0.11

C16-(PEG2)n-LDV liposomes

0.85 ± 0.01

C16-(PEG2)n-LDV SLNs

0.97 ± 0.02
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Figure 4.25: Normalized FRET efficiency of LDV-targeted micelles when diluted 10-fold in
human serum (n=3)
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Figure 4.26: Time resolved emission spectra of Dil + DiO loaded C16-(PEG2)2-LDV
micelles diluted 10-fold in human serum

Figure 4.27. Emission spectra of Dil + DiO C16-(PEG2)2-LDV micelles diluted 10-fold in
triton X-100
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Figure 4.28: Time resolved emission spectra of Dil + DiO loaded C16-(PEG2)4-LDV
micelles diluted 10-fold in human serum

Figure 4.29: Emission spectra of Dil + DiO C16-(PEG2)4-LDV micelles diluted 10-fold in
triton X-100
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Figure 4.30: Time resolved emission spectra of Dil + DiO loaded C16-(PEG2)6-LDV
micelles diluted 10-fold in human serum

Figure 4.31: Emission spectra of Dil + DiO C16-(PEG2)6-LDV micelles diluted 10-fold in
triton X-100
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Figure 4.32: Normalized FRET efficiency of LDV-targeted liposomes when diluted 10-fold
in human serum (n=3)
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Figure 4.33: Time resolved emission spectra of Dil + DiO loaded C16-(PEG2)2-LDV
liposomes diluted 10-fold in human serum

Figure 4.34: Emission spectra of Dil + DiO C16-(PEG2)2-LDV liposomes diluted 10-fold in
triton X-100
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Figure 4.35. Time resolved emission spectra of Dil + DiO loaded C16-(PEG2)4-LDV
liposomes diluted 10-fold in human serum

Figure 4.36: Emission spectra of Dil + DiO C16-(PEG2)4-LDV liposomes diluted 10-fold in
triton X-100
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Figure 4.37: Time resolved emission spectra of Dil + DiO loaded C16-(PEG2)6-LDV
liposomes diluted 10-fold in human serum

Figure 4.38: Emission spectra of Dil + DiO C16-(PEG2)6-LDV liposomes diluted 10-fold in
triton X-100
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Figure 4.39: Normalized FRET efficiency of LDV-targeted solid lipid nanoparticles when
diluted 10-fold in human serum (n=3)
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Figure 4.40: Time resolved emission spectra of Dil + DiO loaded C16-(PEG2)2-LDV solid
lipid nanoparticles diluted 10-fold in human serum

Figure 4.41: Emission spectra of Dil + DiO C16-(PEG2)2-LDV solid lipid nanoparticles
diluted 10-fold in triton X-100
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Figure 4.42: Time resolved emission spectra of Dil + DiO loaded C16-(PEG2)4-LDV solid
lipid nanoparticles diluted 10-fold in human serum

Figure 4.43: Emission spectra of Dil + DiO C16-(PEG2)4-LDV solid lipid nanoparticles
diluted 10-fold in triton X-100
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Figure 4.44: Time resolved emission spectra of Dil + DiO loaded C16-(PEG2)6-LDV solid
lipid nanoparticles diluted 10-fold in human serum

Figure 4.45: Emission spectra of Dil + DiO C16-(PEG2)6-LDV solid lipid nanoparticles
diluted 10-fold in triton X-100
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Table 4.4: Normalized FRET efficiencies of all DiO + Dil FRET dye-loaded micelles,
liposomes and solid lipid nanoparticles in human serum (n=3)
Nanocarrier

Normalized FRET
efficiency n serum

C16-(PEG2)2-LDV micelles

0.51 ± 0.01

C16-(PEG2)4-LDV micelles

0.47 ± 0.01

C16-(PEG2)6-LDV micelles

0.54 ± 0.02

C16-(PEG2)2-LDV liposomes

0.79 ± 0.01

C16-(PEG2)4-LDV liposomes

0.69 ± 0.02

C16-(PEG2)6-LDV liposomes

0.75 ± 0.01

C16-(PEG2)2-LDV SLNs

0.89 ± 0.03

C16-(PEG2)4-LDV SLNs

0.90 ± 0.01

C16-(PEG2)6-LDV SLNs

0.86 ± 0.03
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Table 4.5: Average normalized FRET efficiencies and rate constants of DiO + Dil FRET
dye-loaded micelles, liposomes and solid lipid nanoparticles (n=3)
Nanocarrier

Normalized FRET
efficiency in serum at 1
hour

Rate constant K (1/hr)

C16-(PEG2)n-LDV micelles

0.51 ± 0.04

2.77 ± 0.39

C16-(PEG2)n-LDV liposomes

0.74 ± 0.05

0.61 ± 0.09

C16-(PEG2)n-LDV SLNs

0.88 ± 0.02

0.20 ± 0.05
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4.2

In Vitro Release of Paclitaxel-Loaded Targeted Micelles, Liposomes and SLNs
4.2.1

Introduction. Paclitaxel was loaded into micelles, liposomes and SLNs and

characterized for size, morphology, charge, drug loading efficiency and drug release.
Paclitaxel is a natural anti-cancer agent extracted from taxus with broad spectrum anti-tumor
effects. Paclitaxel is a widely used therapeutic agent that works through cell tubulin
polymerization and inhibition of depolymerization, preventing the formation of normal
mitotic apparatus. However, there are significant challenges associated with the formulation
and administration of paclitaxel due to poor aqueous solubility (≤ 0.3µg/mL), requiring the
use of additional solvents and excipients for effective administration. For example, Taxol is
a commercialized FDA approved product comprising of paclitaxel dissolved in
polyethoxylated castor oil (Cremophor EL) and dehydrated ethanol, which is then diluted in
0.9% normal saline prior to intravenous administration. Unfortunately, Taxol has several
limitations, including precipitation upon dilution and severe side effects due to cremophor
EL, resulting in reduced therapeutic efficacy. To eliminate such side effects and improve
drug solubility, paclitaxel can be loaded into micelles, liposomes and SLNs.
4.2.2

Materials. PAs were synthesized as described in section 2. (CA, USA)

and GenScript (Piscataway, NJ). DPPC lipids and liposome extruder was purchased from
Avanti polar lipids (AL, USA). Solvents including DCM, methanol, ethanol and chloroform
were purchased from fisherscientific (Pittsburg, PA). Paclitaxel was purchased from LC
laboratories. Tripalmitin was purchased from Sigma-Aldrich (MO, USA). Float-A-Lyzer G2
dialysis tubes (MWCO 10,000) were purchased from Spectrum Laboratories (Rancho
Dominguez, CA). Pierce Slide-A-Lyzer G2 dialysis cassettes (MWCO 10,000) were
purchased from VWR (CA, USA).
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4.2.3

Methods.

a) Preparation of paclitaxel-loaded micelles, liposomes and SLNs. Paclitaxelloaded nanocarriers (PTX-liposomes, PTX-micelles and PTX-SLNs) were prepared using
similar methods as for blank nanocarriers (table 4.6). For PTX-liposomes, the hydrophobic
components, DPPC, PA and paclitaxel were dissolved in chloroform: methanol = 2:1 (v/v).
Organic solvents were evaporated to dryness under a stream of nitrogen gas and solvent
traces were removed by leaving the glass tubes under vacuum overnight. The dried lipid film
was then hydrated by the addition of DI water at a temperature between 50⁰C to 55⁰C,
followed by vortexing periodically for 30 minutes to detach any lipid from the glass surface.
Hydration was carried out in a water bath and the temperature was maintained above the
main phase transition temperature (Tm) of lipids (41⁰C for DPPC). This process resulted in
the formation of MLVs, which were subjected to six freeze-thaw cycles with liquid nitrogen
and heated DI water. MLVs were downsized by extruding 21 times each through 0.4µm,
0.2µm, and 0.1µm-pore polycarbonate filters to produce SUVs. Paclitaxel was loaded into
micelles using the solvent evaporation method. In a glass tube, PAs and paclitaxel were
dissolved in methanol. Then methanol was evaporated under nitrogen gas and solvent traces
were removed under vacuum overnight. Next, the dry lipid film was hydrated by the addition
of DI water at a temperature between 50⁰C to 55⁰C, followed by vortexing and sonicating
periodically for 30 minutes to detach any lipid from the glass surface. The resulting mixture
was then centrifuged at 3000 rpm for 1 hour to remove excess paclitaxel and yield a clear
micelle solution. The NanoAsssmblr (Benchtop, Precision NanoSystems Inc., Vancouver,
Canada) was used to prepare PTX-SLNs by microfluidic mixing. Specifically, a microfluidic
cartridge comprising of moulded channels with staggered herringbone structures was used to
formulate PTX-SLNs by mixing of the organic (tripalmitin and paclitaxel in ethanol) and
aqueous (PA in water) phases. The organic and aqueous phases were pumped into two inlets
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of the microfluidic chip using disposable syringes and mixing was controlled by setting the
FRR to 3:1 and the TFR to 15 mL/min. At all steps of preparation, the organic and aqueous
phases were kept at 75⁰C by keeping solutions in the oven and installing a heat block into the
NanoAssemblr instrument. Next, the mixture was collected from the NanoAssemblr and
transferred into G2 slide-A-Lyzer dialysis cassettes (MWCO 10,000) and dialyzed against
water to remove traces of ethanol. Specifically, the dialysis membrane was hydrated in DI
water for 2 minutes prior to insertion of SLN sample. Then the dialysis cassette was stirred
in DI water, which was exchanged every hour for 3 hours. PTX micelles, PTX-liposomes
and PTX SLNs were prepared using all three PAs and each composition was prepared in
triplicates.
b) Paclitaxel loading efficiency for micelles, liposomes and SLNs. Samples were
prepared by diluting nanocarriers 10-fold in methanol and vortexing to ensure complete
solubilization of lipids and paclitaxel. Paclitaxel concentration was determined using
isocratic RP-HPLC (HPLC Agilent 1200 series, Agilent Technologies Inc.) using a C18
column (Agilent 4.6 mm x 250, 5µm) at 25⁰C. The mobile phase consisted of
acetonitrile/water (70/30, v/v) at a flow rate of 1.0 mL/min. Paclitaxel was detected with
ultraviolet (UV) detection at 227 nm using 20µl injection volumes. A calibration curve was
generated by plotting known concentrations of paclitaxel against peak area using a series of
standards ranging between 1µg/ml to 100 µg/ml. The standard curve was used to determine
the concentration of paclitaxel in PTX-micelles, PTX-liposomes and PTX-SLNs. Drug
Loading Content (DLC) and Drug Loading Efficiency (DLE) was determined using equations
4.1 and 4.2:
QRSTUV SL WBX YU UMUSZM[[Y\[

Equation 4.1 𝐷𝐿(%) = QRSTUV SL WBX ]SM^\^ UMUSZM[[Y\[_ x 100

Equation 4.2 𝐷𝐿𝐸(%) =

QRSTUV SL WBX YU UMUSZM[[Y\[
QRSTUV SL WBX T_\^ LS[ Va\ b[\bM[MVYSU UMUSZM[[Y\[_

x 100
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c) Determination of size, PDI, zeta potential and morphology. The size, PDI and
zeta potential of PTX-liposomes and PTX-SLNs were determined using DLS on the Zetasizer
ZS 90 (Malvern Instruments, Ltd., Malvern, UK). For nanocarrier size, PDI and zeta
potential, measurements were taken in a disposable microcuvette at 25°C. For each sample,
measurements were taken three times. The morphology and size of PTX-micelles, PTXliposomes and PTX-SLNs was determined by Nanoimaging Services Inc (San Diego, CA)
using a FEI Tecnai T12 electron microscope (serial number D1100), operating at 120keV
equipped with a FEI Eagle 4k x 4k CCD camera. For Electron Microscope (EM) grid
preparation, 3µl of each nanocarrier sample was applied to a cleaned 400-mesh copper grid
and blotted away with filter paper. Next, vitrification was carried out in liquid ethane and
these vitreous ice grids were transferred into the EM using a cryostage that maintains the
grids at a temperature below -170⁰C. Images of each grid were acquired at multiple scales to
assess the overall distribution of the specimen. After identifying potentially suitable target
areas for imaging at lower magnifications, high magnification images were acquired at
nominal magnifications of 110,000x (0.10 nm/pixel), 52,000x (0.21 nm/pixel) and 21,000x
(0.50 nm/pixel). The images were acquired at a nominal underfocus of -5.0μm to -1.0μm and
-

2

electron doses of ~10-25 e /Å .
d) Determination of in vitro drug release. Dialysis tubes (Float-A-Lyzer G2,
MWCO 10,000) were used to determine in vitro release profiles of PTX-micelles, PTXliposomes and PTX-SLNs. Dialysis devices containing 1mL of nanocarrier sample was
placed into 4 liters of DI water at 37⁰C and magnetically stirred. At predetermined time
points up to 24 hours, aliquots (20 µl) of nanocarrier sample were removed from the dialysis
tube and paclitaxel content was analyzed using HPLC as described above. The release
profiles were analyzed using non-linear regression analysis performed by GraphPad Prism
software. The release rate constants and time to release 50% of drug (t50%) from micelles,
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liposomes and SLNs were determined and statistically compared using one-way ANOVA
followed by the Tukey multiple comparison test. A P-value of <0.05 was considered
statistically significant.
4.2.4

Results and discussion.

a) Physicochemical characterization of paclitaxel-loaded nanocarriers. The
physicochemical characterization and drug loading of PTX-micelles, PTX-liposomes and
PTX-SLNs such as hydrodynamic size, zeta potential and DLC are summarized in tables 4.7
and 4.8. DLS results showed that there was no significant difference between the
hydrodynamic sizes of all PTX-liposomes and these ranged between 117.27 ± 8.08 nm and
129.00 ± 8.32 nm. The hydrodynamic sizes of all PTX-SLNs was also similar and ranged
between 74.40 ± 4.39 nm and 84.4 ± 2.77 nm. The hydrodynamic sizes of micelles could not
be determined by DLS, therefore cryoTEM was used to determine the size and morphology
of PTX-micelles (figure 4.46). For these micelles, the images showed roughly round
particles between 6 nm to 12 nm, which are significantly smaller than the sizes of blank
micelles characterized by TEM. This effect of size reduction of drug-loaded micelles
compared to blank micelles has previously been observed and may be explained by the
intermolecular interactions between paclitaxel and the core of the micelle [68, 69]. Paclitaxel
is physically incorporated in the core of micelles, enhancing the hydrophobic interactions
resulting in the formation of smaller particles. CryoTEM imaging of PTX-liposomes
revealed unilamellar particles with rounded to angular appearance, ranging between 48-145
nm in their longest dimension. PTX-liposomes had an interior density that was similar to the
density of the surrounding aqueous medium, indicating the presence of a hydrophilic core
that is commonly found in liposomes. The outer layer of the particles resembled a lipid
bilayer which has a thickness of 6 to 7.5 nm in width. The sample also contained many short
narrow particles ranging between 20 to 40 nm in length and 5 to 7 nm in width as well as
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some round to oblong particles that were 20 to 40 nm in their longest dimension, which are
likely different views of lipid-based, disk-shaped particles. PTX-SLNs were also imaged and
revealed particles ranging from 10 to 120 nm that were mostly round to oblong and
occasionally angular in appearance. Particles had an interior density that was slightly denser
than the surrounding aqueous solution, indicating the presence of a lipid core. The sample
also contained a few short narrow particles with a length of 12 to 30 nm and a width of 6 to
14 nm. In general, DLS results showed that sizes of PTX-SLNs were smaller than PTXliposomes (80.53 ± 5.37 nm vs 123.31 ± 5.87 nm) and PDI values were ≤0.2. CryoTEM
results confirmed the smaller size range of PTX-SLNs (10-120 nm) compared to PTXliposomes (48-145 nm) and PTX-micelles had the smallest sizes between 6 to 12 nm.
Although the smaller sizes of PTX-micelles may increase uptake and tumor penetration, the
size of these micelles fall outside the ideal nanocarrier size range (10-100 nm), where sizes
smaller than 10 nm may be easily excreted by the kidneys. PTX-liposomes and PTX-SLNs
showed ideal size ranges. Zeta potential values ranged between -23.61 ± 10.23 mV and 51.65 ± 10.82 mV for PTX-micelles, PTX-liposomes and PTX-SLNs, which is attributed to
the carboxylate group present in the peptide. The highly negative charge of these nanocarriers
provides good colloidal stability and may help to prevent interactions with opsonins [70, 71].
However, negatively charged particles may prevent efficient cellular uptake due to the
negatively charged cellular membrane[72, 73].
b) Paclitaxel loading efficiency of micelles, liposomes and SLNs. Drug loading
into micelles depend upon the partitioning of lipophilic drug molecules into the micelle core
and the extent to which this occurs can be described by the partition coefficient. In particular
an increase in the length of the hydrophobic region will improve the partitioning behavior of
hydrophobic drugs into the micelle core. There are several factors that affect the drug loading
efficiency of micelles, which include the compatibility of the drug with the core forming
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component of the micelle, the hydrophobicity, nature and length of the core-forming segment,
the length and nature of the corona-forming component, the interactions between the drug
and core and the method of micelle preparation. In general, the larger the hydrophobic
segment, the larger the core for increased drug entrapment. An increase in the hydrophilic
segment results in an increase in the CMC and reduced drug loading [74-76]. For all PTXmicelles, the DLC and DLE was low: ranging between 1.28 ± 0.07 wt % to 2.11± 0.46 wt %
and 12.88 ± 0.75 % to 21.13 ± 4.59 % (table 4.7) which is typically seen for micelles with
DLC’s ranging between 1-20 wt% [77]. The highest DLC was achieved for C16-(PEG2)2LDV PTX-micelles, which is likely due to the increased hydrophobicity and lower CMC
value. Like micelles, efficient drug loading is highly dependent on the compatibility of drug
molecules with the hydrophobic segment of the nanocarrier. For efficient drug loading into
liposomes, the drug must be significantly hydrophobic with high log P values
(≥ 3) for partitioning into the hydrophobic region of the phospholipid bilayers. Paclitaxel has
a log P value of 3.6 and can be loaded into liposomes, which has been demonstrated through
the development of Lipusu currently on the market and LEP-ETU currently undergoing
clinical trials [38, 78]. However, the bulky and asymmetric nature of paclitaxel makes
liposomal drug loading challenging and often leads to paclitaxel leakage or precipitation
immediately after preparation or during storage. Consequently, it was shown that that only
≤3.3 mol% can be loaded into lipid bilayers, resulting in poor drug loading efficiency [79].
In the initial studies, paclitaxel was loaded into liposomes at similar lipid concentrations to
micelles (1mg/mL), however these vesicles were unstable and aggregated, which was likely
due to an insufficient amount of lipid available to effectively retain paclitaxel in the
phospholipid bilayer. Furthermore, initial drug loading at 10 wt% resulted in destabilization
of vesicles, indicating that an optimal balance between lipid concentration and paclitaxel
concentration was required to produce stable vesicles. Subsequently, stable PTX-liposomes
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were produced when prepared at higher lipid concentrations (15 mg/mL) and lower initial
DLC at 1 wt%, which resulted in drug loading capacities ranging between 0.83 ± 0.41 wt% to
1.00 ± 0.01 wt% and DLE’s ranging between 63.93 ± 31.85 % and 106.51 ± 0.68 % (table
4.7). Compared to PTX-micelles and PTX-liposomes, PTX-SLNs demonstrated the highest
DLC and DLE with values ranging between 7.14 ± 0.17 wt% to 7.91 ± 0.87 wt% and 71.49 ±
1.66 % to 79.15 ± 8.65 % respectively (table 4.7). This is likely due to the use of high
melting point triglycerides that help to increase paclitaxel incorporation and retention inside
the lipid matrix. These results showed that paclitaxel was efficiently loaded into PTXmicelles, PTX-liposomes and PTX-SLNs and the variation in DLE’s may be due to
nanocarrier structure, lipid compatibility with drug and methods used for producing
nanocarriers.
a) Determination of in vitro drug release. Upon systemic administration,
nanocarriers must extravasate into the tumor and either undergo interstitial drug release or
intracellular release. Therefore, nanocarriers must be designed to demonstrate drug release in
a controlled sustained release manner for enabling drug accumulation in the tumor. For
example, Doxil is a liposomal formulation encapsulating doxorubicin and delivers 10 to 15
times more drug to the tumor compared to free doxorubicin. However, the bioavailability of
Doxil is only 40 to 50% due to slow release, indicating that the excessive stability of this
formulation is problematic [80]. Conversely, a polymeric micelle formulation Genexol-PM
encapsulating paclitaxel has been shown to be too unstable upon systemic administration,
where paclitaxel partitions out of the micelle and interacts with serum proteins, resulting in
premature drug release before reaching the target site [80]. Therefore, the key challenge is to
develop nanocarriers that maintain stability before reaching the tumor whilst allowing for
efficient release when reaching the tumor site. In this study, the in vitro release profiles of
PTX-micelles, PTX-liposomes and PTX-SLNs were compared to provide an indication of the
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ability of these nanocarriers to retain drug under sink conditions. Compared to PTXliposomes and PTX-SLNs, the release rate of paclitaxel from micelles was the fastest with
≥95% of the drug being released over 4 hours (figure 4.49). This is likely due to the dynamic
nature of micelles, disassembly of micelles or rapid diffusion of paclitaxel from the micelles
under sink conditions. Paclitaxel was released from liposomes at a slower rate than PTXmicelles, with ≈20% of drug release by 4 hours and ≈60% released over 24 hours (figure
4.50). These results demonstrate that PTX-liposomes have improved drug retention
properties over PTX-micelles, presumably due to the more rigid and mechanical structure of
the phospholipid bilayer membrane. All PTX-SLNs exhibited the slowest release rate
compared to PTX-micelles and PTX-liposomes, where only 3-13% of PTX was released over
4 hours and 16-40% released over 24 hours (figure 4.51). These results showed a significant
increase in drug retention in PTX-SLNs compared to PTX-micelles and PTX-liposomes,
which is likely due to the core-forming high melting point triglyceride, which may have
significantly decreased the mobility of paclitaxel molecules within the lipid core, reducing
drug leakage [81]. In contrast, PTX-liposomes are formed from DPPC lipids which have a
gel-to-liquid phase transition temperature (41⁰C) that is close to the body temperature,
increasing the membrane fluidity and probability of paclitaxel molecules leaking out of the
phospholipid bilayer membrane [82, 83]. The differences in release rates between PTXmicelles, PTX-liposomes and PTX-SLNs are described by release rate constants and t50%
values presented in table 4.8. The release rate constants were the highest for PTX-micelles
compared with PTX-liposomes and PTX-SLNs (0.80 ± 0.09/hr vs 0.08 ± 0.03/hr and
0.02±0.01/hr). One-way ANOVA results showed that there was a significant difference
between the t50% values of PTX-micelles, PTX-liposomes and PTX-SLNs (p=0.03).
Specifically, the t50% values for PTX-micelles were significantly lower compared to PTXliposomes and PTX-SLNs. The Tukey test revealed a significant difference with PTX-
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micelles vs PTX-SLNs (p=0.03) and PTX-liposomes vs PTX-SLNs (p=0.06). However,
there was no significant difference in t50% values of PTX-micelles vs PTX-liposomes
(p=0.84).

119

Figure 4.46: CryoTEM image of paclitaxel-loaded LDV targeted-micelles at a magnification
of 52,000x. Observed in the sample are small particles that vary in size (yellow arrows), and
larger densities that possibly represent clusters of small particles (blue arrow). Scale Bar: 200
nm

120

Figure 4.47: CryoTEM image of paclitaxel-loaded LDV-targeted liposomes at a
magnification of 52,000x. Observed in the sample are unilamellar particles with a round
angular appearance and with an interior density similar to that of the surrounding aqueous
solution (red arrow); elongated particles (cyan arrow); round to elongated faint particles
(green arrow); small particles (yellow arrow). Scale Bar: 200 nm
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Figure 4.48: CryoTEM image of paclitaxel-loaded LDV-targeted solid lipid nanoparticles at
a magnification of 52,000x. Observed in the sample are particles of various sizes that have an
interior density that is slightly more dense than that of the surrounding buffer and are roughly
round (orange arrow); angular or oblong in shape (purple in shape); small and elongated
particles (cyan arrow); small particles (yellow arrow). Scale Bar: 200 nm
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Figure 4.49: In vitro release profiles of paclitaxel-loaded LDV-targeted micelles in aqueous
solution (n=3)

Figure 4.50: In vitro release profiles of paclitaxel-loaded LDV-targeted liposomes in aqueous
solution (n=3)
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Figure 4.51: In vitro release profiles of paclitaxel-loaded LDV-targeted solid lipid
nanoparticles in aqueous solution (n=3)

Figure 4.52: Summary of in vitro release profiles of paclitaxel-loaded LDV targeted micelles,
liposomes and SLNs in aqueous solution
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Table 4.8: Average size, DLC, DLE, rate constants and t50% values for paclitaxel-loaded
micelles, liposomes and solid lipid nanoparticles (n=3
Nanocarrier

DLC (%)

DLE (%)

Size (nm)

Rate constant
K (1/hr)

PTX-micelles

1.70 ± 0.41

17.06 ± 4.12

-

0.80 ± 0.09

0.87 ± 0.10

PTX-liposomes

0.92 ± 0.08

80.82 ± 22.61

123.31 ± 5.98 0.08 ± 0.03

9.15 ± 3.12

PTX-SLN

7.44 ± 0.41

74.39 ± 4.15

80.53 ± 5.37

51.41 ± 30.99

0.02 ± 0.01

t50%
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4.3 Spray Drying of Paclitaxel-loaded LDV Targeted Micelles, Liposomes and SLNs
4.3.1

Introduction. One of the challenges faced with lipid-based nanocarriers is

their relative instability in aqueous dispersions. Lipid nanocarriers can undergo physical and
chemical degradation, resulting in decreased safety and loss of therapeutic efficacy.
Chemical degradation can occur through the oxidation of fatty acid chains and the hydrolysis
of ester bonds, resulting in the generation of free fatty acids, lysophospholipids and
phospholgycerol compounds. Physical instability occurs through vesicle fusion, aggregation
and drug leakage [84]. These factors combined affect the quality of the final product,
resulting in poor therapeutic efficacy and safety concerns. For example, commercially
available liposome products such as DOXIL are known to become unstable in solution,
where drug leakage and liposome aggregation occurs [85]. To overcome these obstacles,
aqueous dispersions of nanocarriers can be converted into a dry powder which can be stored
over a long period of time but can be reconstituted at the time of administration. As a result,
stabilization is achieved by reducing the water content and the shelf-life is increased.
Currently, lyophilization or freeze-drying are the most common methods for drying
pharmaceutical products. Freeze-drying involves the freezing of nanocarriers in aqueous
solution followed by the removal of water from frozen samples by sublimation under
vacuum. However, during this process, the nanoparticles are subjected to freezing and drying
stresses, which may result in nanocarrier destabilization. For example, freezing can cause the
disruption of liposome bilayer membrane structure due to the liquid-ice interface resulting in
aggregation and vesicle fusion [86]. Furthermore, freeze-drying requires expensive
equipment and may take several days to complete. To overcome the limitations faced with
freeze-drying, spray drying can be used to convert lipid-based nanocarriers into dry powders
using a single step. Spray drying is carried out through three stages, namely atomization,
dehydration and powder collection. Initially, the feedstock solution which is the nanocarrier
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in aqueous solution is atomized into a hot drying gas such as nitrogen. Atomization involves
the application of an energy source that acts on a bulk liquid, resulting in the liquid break up
into individual spray droplets. Following atomization, microparticle formation occurs
through the conversion of atomized spray droplets into solid particles. The solid particles are
then separated from the process gas stream using a cyclone and this principle is based on the
density difference between the particle and gas. During the spray drying process, heat and
high shearing forces can result in the degradation of lipid components, therefore optimization
of formulation and process parameters is critical to maintain the integrity of nanocarriers
during spray drying. For example, carbohydrate excipients such as mannitol, sucrose or
trehalose are added into the feed to serve as bulking agents or protectants that result in the
formation of microparticles embedded with nanocarriers [78, 87]. Other excipients such as
amino acids and peptide sequences have also proved useful in spray drying by protecting
against thermal stresses and denaturation, stabilization against aggregation and oxidation and
reducing the hygroscopicity of various formulations [88]. For example, L-leucine has been
used as an excipient for spray drying with lipid-based nanocarriers, due to hydrophobic and
surfactant-like properties that enable migration to the surface of particles during the drying
process, resulting in deaggregation and stabilization of particles [89-91]. In this study,
selected PTX-micelles, PTX-liposomes and PTX-SLNs were spray dried with trehalose or a
combination of trehalose and L-leucine.

128
4.3.2

Materials. PAs were synthesized at GenScript (Piscataway, NJ). DPPC

lipids and liposome extruder were purchased from Avanti polar lipids (AL, USA). Solvents
including DCM, methanol, ethanol and chloroform were purchased from fisherscientific
(Pittsburg, PA). Paclitaxel was purchased from LC laboratories. Tripalmitin and D-(+)Trehalose Dihydrate was purchased from Sigma-Aldrich (MO, USA). Pierce Slide-A-Lyzer
G2 dialysis cassettes (MWCO 10,000) were purchased from VWR (CA, USA). L-leucine,
aluminum stubs and carbon adhesive tapes were provided by AstraZeneca (SSF, USA).
4.3.3

Methods.

a) Spray drying of paclitaxel-loaded micelles, liposomes and SLNs. Initially, one of
each type of nanocarrier was selected to determine the feasibility for spray drying. Upon
evaluation, PTX-micelles formed from C16-(PEG2)4-LDV PAs were chosen since this
nanocarrier has the lowest CMC value, small size and suitable water solubility for
formulation preparation. PTX-liposomes and PTX-SLNs formed from C16-(PEG2)4-LDV
PAs were then selected for spray drying for direct comparison. PTX-micelles, PTXliposomes and PTX-SLNs were prepared using the cosolvent evaporation method, thin-film
hydration/extrusion method and microfluidic technology as previously described. To
determine which excipients are required to form stable nanocarriers upon spray drying,
nanocarriers were spray dried in trehalose only or in a mixture of trehalose and l-leucine. For
feedstock preparation, 50mg of PTX-micelles, PTX-liposomes and PTX-SLNs were mixed
with excipients (trehalose, L-leucine) dissolved in water at 2.5 wt% (table 4.9) and the total
feedstock concentration was 20 mg/ml. The feedstock solution was then spray dried using a
custom designed small-scale pharmaceutical spray dryer. The dryer inlet temperature was
maintained at 60°C; the dryer outlet temperature was maintained at 50°C. The drying gas
flow rate was maintained at 850 slpm (standard liters per minute) with an atomization gas
flow rate of 15 slpm. The collector jacket temperature and the cyclone jacket temperatures
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were maintained at 50⁰C. The feedstock solution was fed into the spray dryer at rate of
3 mL/min, which resulted in the deposition of spray dried material in a collector. Next, the
collector containing the spray dried powders was transferred into a glove box and the
powders were then subsequently transferred into glass sample jars using a spatula. The tare
and gross weights of the collector and sample jars were then recorded and the production
yield was calculated from the mass ratio of the collected powders to the total solid in the
feed. Sample handling was performed in a glove box with constant flushing of nitrogen.
Prior to characterization, spray dried powders were kept in a dry box at low relative humidity
(≤5%).
b) Moisture content of spray dried powders. The residual moisture content of all
spray-dried powders were determined by the oven vaporizer Karl Fisher coulometric titration
method using a Metrohm 874 oven sample processor (Switzerland). The oven temperature
was set to 150⁰C and the gas flow to 75mL/min. Samples were prepared by weighing out
approximately 15mg of spray-dried powder into vials and sealed with caps. Blank samples
were also prepared by sealing an empty vial. All samples were prepared in triplicate and
analyzed using Tiamo 2.5 software. The moisture content was determined using the equation
4.3.

Equation 4.3:

𝑀𝑜𝑖𝑠𝑡𝑢𝑟𝑒 𝐶𝑜𝑛𝑡𝑒𝑛𝑡 (%) =

mMV\[ F\V\ZV\^ (Tn)
oMRb]\ pM__ (Tn)
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c) Differential Scanning Calorimetry (DSC). DSC measurements for all spray-dried
powders were performed using a differential scanning calorimeter (DSC Q2000 TA, USA).
Approximately 15mg of spray dried powder was loaded into an aluminum pan and
hermetically sealed. The sample was heated at the scanning rate of 2°C/min to 150⁰C in a
nitrogen atmosphere. All samples were prepared in triplicate and analyzed using the TA
instrument explorer Qseries software.
d) Morphology of spray dried powders. The morphology of spray-dried powders
were evaluated using Scanning Electron Microscopy (SEM). Sample preparation was carried
out in a glove box under constant flushing with nitrogen and the relative humidity was kept
below 5%. Spray-dried powders were deposited onto an aluminum stub coated with
conductive carbon tape. The aluminum stubs coated with sample were then sputter coated
with gold-palladium for 60 seconds under high vacuum. SEM imaging was performed using
a JSM-IT100 microscope (JOEL Ltd., USA), operating at an acceleration voltage of 20 kV.
e) Reconstitution and characterization of paclitaxel-loaded nanocarriers. Spray
dried powders were reconstituted with purified water and agitated for approximately 5
minutes by hand until all the powder had dissolved. The final lipid concentration upon
reconstitution was 0.5 mg/mL. Following reconstitution, the size, PDI and charge were
characterized using the mobius zeta Potential and DLS detector (Wyatt, CA, USA). The
paclitaxel content was determined using the HPLC method previously described.
f) Determination of stability. The stability of paclitaxel-loaded nanocarriers before
and after spray drying was carried out by determination of size, PDI and paclitaxel content
over 7 days at room temperature and at 4⁰C. The size and PDI was determined using the
mobius zeta Potential and DLS detector (Wyatt, CA, USA). Paclitaxel content was
determined using the HPLC method previously described.
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Table 4.9: Composition of spray dried formulations
Name of formulation

Component (wt%)

PTX-micelles/trehalose

nanocarrier (2.5 wt%)
trehalose (97.5 wt%)

PTX-liposomes/trehalose

nanocarrier (2.5 wt%)
trehalose (97.5 wt%)

PTX-SLN/trehalose

nanocarrier (2.5 wt%)
trehalose (97.5 wt %)

PTX-micelles/trehalose/leucine

nanocarrier (2.5 wt%)
trehalose (77.5 wt%)
leucine (20 wt%)

PTX-liposomes/trehalose/leucine

nanocarrier (2.5 wt%)
trehalose (77.5 wt%)
Leucine (20 wt%)

PTX-SLN/trehalose/leucine

nanocarrier (2.5 wt%)
trehalose (77.5 wt %)
leucine (20 wt%)
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4.3.4

Results and discussion. Nanocarriers prepared and stored as aqueous

dispersion are known to undergo physical and chemical changes over time. Therefore,
conversion of nanocarriers dispersions to a powder form is highly desired to improve the
long-term stability. The drying method, process parameters and formulation excipients need
to be carefully selected to ensure that nanocarriers can be re-dispersed without any significant
size change, aggregation or loss of drug content. Furthermore, the spray dried powders
should remain stable with low residual moisture content, to prevent chemical degradation of
the formulation components. In this study, selected PTX-micelles, PTX-liposomes and
PTX-SLNs were successfully spray dried with either trehalose or a mixture of trehalose and
L-leucine to stabilize the nanocarriers. The choice of spray drying excipients did not
significantly affect the yield, which ranged between 71.5% to 83.5% across all spray dried
powder formulations (table 4.10 and figure 4.53). Many spray dried powders contain
carbohydrates in their amorphous state and since amorphous components are
thermodynamically unstable and there is a driving force for crystallization to occur, a high
transition temperature of powders is highly desirable. Trehalose comprises the bulk of the
spray dried formulations and was selected due to the high transition temperature. Increased
moisture content can significantly decrease the transition temperature of spray dried powders,
since water acts as a plasticizer, causing the mobilization of amorphous content [92].
Consequently, powders with increased moisture content can have reduced transition
temperatures, increasing the chances of forming physically unstable powders. The oven KF
results showed that the residual moisture content for all spray dried powders was very low at
values <2% (table 4.11) and did not affect the transition temperatures of all spray dried
formulations. This was demonstrated through the DSC results showing mid-point transition
temperature values ranging between 95.07 ± 0.86 °C and 100.77 ± 0.00 °C (table 4.12)
(figures 4.54 to 4.59) which are representative of trehalose. SEM images showed smooth
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surface and spherical morphology of powders spray dried with trehalose. In contrast,
powders spray dried with both trehalose and L-leucine showed corrugated particles with
wrinkled morphology (figure 4.60). Formulations with wrinkled morphology are attributed
to the presence of L-leucine which precipitates out earlier in the drying process due to its
lower solubility. This results in a solid shell that collapses later in the drying process. In
contrast, formulations with highly water-soluble excipients such as trehalose continually
shrink as liquid droplet dries, eventually forming particles with smooth morphology [88, 93,
94]. To determine whether the nanocarriers had maintained their integrity after spray drying,
the spray dried powders were reconstituted in purified water and the size/PDI was measured
using DLS. The results showed that the size of PTX-liposomes decreased from 107 nm to
93.33 nm and the PDI decreased from 0.236 to 0.149 after spray drying with trehalose (table
4.13 and 4.14, figure 4.61 and 4.62). The same trend was observed for PTX-SLNs which
showed a decrease in size from 90.80 nm to 74.20 nm (table 4.13 and table 4.14, figure 4.63).
Particle size reduction in the presence of cryoprotectants has been recently observed and may
be due to the interactions of trehalose with the nanocarrier [95]. Conversely, the sizes of
liposomes increased from 107.60 nm to 138.53 nm when spray drying with trehalose and Lleucine (figure 4.61, table 4.13). This effect has previously been observed where
concentrations of L-leucine at 1% (w/w) increased the size of liposomes significantly after
spray drying [89]. This is likely due to the partitioning of hydrophobic amino acid L-leucine
into the lipid membrane during drying, causing aggregation of the vesicles [89].
Furthermore, it has also been demonstrated that amino acids with hydrocarbon side chains
can cause damage to the lipid membranes of vesicles during freeze/thaw processes [96]. Lleucine also influenced the size and PDI of PTX-SLNs since these powders did not dissolve
completely upon reconstitution and required syringe filtration to remove undissolved
particles. Despite these changes, all spray dried PTX-liposomes and PTX-SLNs maintained
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nanosizes close to 100 nm upon reconstitution. The stability of reconstituted PTX-SLNs and
PTX-liposomes was determined by measuring the size, PDI and paclitaxel content over 7
days at room temperature or at 4°C (figures 4.67 to 4.72). The results showed no significant
change in size, PDI and paclitaxel content over 7 days at 4°C. There was also no significant
change in the size and PDI of PTX-SLNs and PTX-liposomes at room temperature over 7
days. However, a decrease in the paclitaxel content of nanocarriers was observed over 7 days
at room temperature except for PTX-SLNs and PTX-micelles spray dried in trehalose.
Overall, the short-term stability studies showed that the reconstituted nanocarriers were stable
for up to 7 days at 4°C. Further studies are required to characterize the long-term stability of
these formulations.
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Table 4.10: Yields of spray dried formulations
Formulation

Yield (%)

PTX-micelles/trehalose

71.5

PTX-liposomes/trehalose

79.5

PTX-SLN/trehalose

80.5

PTX-micelles/trehalose/leucine

74.5

PTX-liposomes/trehalose/leucine

83.5

PTX-SLN/trehalose/leucine

79.5

Figure 4.53: Yields of spray dried formulations
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Table 4.11: Residual moisture content of spray dried formulations (n=3)
Formulation

Water (%)

PTX-micelles/trehalose

1.29 ± 0.05

PTX-liposomes/trehalose

1.85 ± 0.01

PTX-SLN/trehalose

1.42 ± 0.01

PTX-micelles/trehalose/leucine

1.08 ± 0.03

PTX-liposomes/trehalose/leucine

1.44 ± 0.04

PTX-SLN/trehalose/leucine

1.01 ± 0.03

Table 4.12: Transition temperatures of spray dried formulations (n=3)
Formulation

Tg Onset (°C)

Mid-Point Tg (°C)

PTX-micelles/trehalose

97.65 ± 0.83

100.77 ± 0.00

PTX-liposomes/trehalose

94.26 ± 2.97

98.91 ± 0.00

PTX-SLN/trehalose

96.33 ± 0.02

98.10 ± 0.10

Liposomes/Trehalose/Leucine

90.98 ± 0.80

95.17 ± 1.43

Micelles/Trehalose/Leucine

92.11 ± 0.09

95.07 ± 0.86

SLN/Trehalose/Leucine

95.39 ± 0.77

98.23 ± 0.77
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Figure 4.54: DSC-thermogram of spray dried PTX-micelles/trehalose

Figure 4.55: DSC-thermogram of spray dried PTX-liposomes/trehalose
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Figure 4.56: DSC-thermogram of spray dried PTX-SLN/trehalose

Figure 4.57: DSC-thermogram of spray dried PTX-micelles/trehalose/leucine
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Figure 4.58: DSC-thermogram of spray dried PTX-liposomes/trehalose/leucine

Figure 4.59: DSC-thermogram of spray dried PTX-SLN/trehalose/leucine
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Figure 4.60: Scanning Electron Microscope images of spray dried formulations (PTXmicelles/trehalose, PTX-liposomes/trehalose, PTX-SLN/trehalose, PTXSLN/micelles/trehalose/leucine, PTX-liposomes/trehalose/leucine, PTXSLN/trehalose/leucine).
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Table 4.13: Sizes of paclitaxel-loaded liposomes and solid lipid nanoparticles before and after
spray drying (SD) (n=3)
Formulation

Size before SD (nm)

Size after SD
in trehalose (nm)

Size after SD in
trehalose/leucine (nm)

PTX-liposomes

107.60 ± 3.10

93.33 ± 2.95

138.53 ±17.31

PTX-SLN

90.80 ± 1.11

74.20 ± 2.95

121.20 ± 8.98

PTX-micelles

ND

ND

ND

Table 4.14: PDI of paclitaxel-loaded liposomes and solid lipid nanoparticles before and after
spray drying (SD) (n=3)

Formulation

PDI before SD

PDI after SD
in trehalose

PDI after SD in
trehalose/leucine

PTX-liposomes

0.236 ± 0.001

0.149 ± 0.007

0.237 ± 0.003

PTX-SLN

0.236 ± 0.002

0.224 ± 0.005

0.131 ± 0.025

PTX-micelles

ND

ND

ND
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Figure 4.61: Size of paclitaxel-loaded liposomes before and after spray drying
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Figure 4.62: PDI of paclitaxel-loaded liposomes before and after spray drying
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Figure 4.63: Size of paclitaxel-loaded solid lipid nanoparticles before and after spray drying
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Figure 4.64: PDI of paclitaxel-loaded solid lipid nanoparticles before and after spray drying
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Figure 4.65: Size of reconstituted spray dried paclitaxel-loaded liposomes and solid lipid
nanoparticles measured over 7 days at 4⁰C (n=3)

Figure 4.66: PDI of reconstituted spray dried paclitaxel-loaded liposomes and solid lipid
nanoparticles measured over 7 days at 4⁰C (n=3)
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Figure 4.67: Size of reconstituted spray dried paclitaxel-loaded liposomes and solid lipid
nanoparticles measured over 7 days at room temperature (n=3)

Figure 4.68: PDI of reconstituted spray dried paclitaxel-loaded liposomes and solid lipid
nanoparticles measured over 7 days at room temperature (n=3)
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Figure 4.69: Graph showing the paclitaxel content of spray dried micelles, liposomes and
solid lipid nanoparticles measured over 7 days at 4⁰C

Figure 4.70: Graph showing the paclitaxel content of spray dried micelles, liposomes and
solid lipid nanoparticles measured over 7 days at room temperature
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Chapter 5: In Vivo Efficacy of Paclitaxel-loaded Micelles, Liposomes and SLNs
5.1. Introduction
To evaluate the in vivo efficacy of drug-loaded nanocarriers, xenograft models of
human tumors grown in immunodeficient mice are developed by injection or implantation of
human tumor cells in mice. Once tumor growth has been established, mice are injected with
drug-loaded nanocarriers and the anti-cancer efficacy can be determined by evaluating tumor
growth progression over time and determination of the tumor mass at the end of the study.
Other parameters such as body weight can be monitored throughout the course of the study to
determine toxic effects of nanocarriers. To maximize therapeutic efficacy, nanocarriers must
demonstrate sufficient stability for extended in vivo circulation half-life, reduced drug leakage
during circulation, maintenance of nanosize for tumor penetration and degradation for reduced
systemic toxicity [97]. In this study, nanocarriers spray dried with trehalose were selected to
compare the in vivo anti-cancer efficacy of PTX-micelles, PTX-SLNs and PTX-liposomes.
5.2 Materials
Spray dried PTX-micelles, PTX-liposomes and PTX-SLNs were prepared at
AstraZeneca (SSF, CA). Cremophor EL was purchased from Spectrum Chemicals. The
following materials were purchased by LoveLace Biomedical: A375 adherent malignant
human melanoma cell line was obtained from ATTC (VA, USA). NCI Athymic NCr-nu/nu
mice were purchased from Charles River Laboratories (San Diego CA, USA).
5.3 Methods
The in vivo animal study was conducted by Lovelace Biomedical (Albuquerque, NM)
according to protocol (No. FY17-078) reviewed and approved by the Institutional Animal
Care and Use Committee (IACUC). The tumor regression effect was evaluated in 3 to 5week-old (15 to 25g) female NCI Athymic NCr-nu/nu mice obtained from Charles River
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Laboratories. All animals were injected with A375 human melanoma cells at a target of 106
cells per animal by subcutaneous injection into the right or left posterior flank or on the back.
Following tumor growth, animals were randomized into five treatment groups with targeted
minimum group sizes of six mice per treatment group: (Trehalose, Taxol, PTX-micelles,
PTX-liposomes and PTX-SLNs). PTX-micelles, PTX-liposomes and PTX-SLNs were
provided to LoveLace Biomedical in spray dried powder form and were reconstituted in
sterile water for injection prior to in vivo administration. Each group was treated by tail vein
injection twice weekly and treatments were given at a paclitaxel dose of 50µg/kg for up to 4
weeks. The tumor volume was measured three times weekly using equation 5.1[98]:

Equation 5.1

V = length * (width)2/2.

The body weight of mice in each group was measured three times weekly. Tumor volume
and weight and body weight were determined at necropsy. Mice were euthanized based on
the moribund/euthanasia criteria according to LoveLace biomedical protocol, which includes,
difficulty or inability to reach food or water, reluctance to move when stimulated to do so,
25% or greater pre-challenge body weight loss from the highest body weight measurement
and tumor volume sizes reaching over 4000 mm3. The data was analyzed by GraphPad Prism
and the software was used to plot tumor volume v/s treatment day and the differences in
tumor volume were statistically evaluated. The differences in tumor volume between groups
were compared using repeated-measures one-way ANOVA (mixed-effects model) followed
by Tukey post hoc comparisons. A p value <0.05 was considered statistically significant.
The tumor growth inhibition (TGI) was calculated using equation 5.2, where T indicates the
mean tumor volume of the treatment group and C indicates the mean tumor volume of the
control group [99]. In vitro-in vivo correlations were analyzed by simple linear regression.
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Equation 5.2

TGI (%) = (1-T/C) *100

5.4 Results and Discussion
The anti-tumor efficacy of PTX-micelles, PTX-liposomes and PTX-SLNs was
evaluated in tumor-bearing mice. For the control group (trehalose), PTX-micelle group and
PTX-liposomes group, a number of mice were either moribund or had died on day 26 and 29
(figure 5.1). The statistical analysis results showed significant differences in tumor volumes
between groups (p<0.0001). Tukey’s multiple comparison test revealed statistically
significant differences in tumor volumes between control and taxol groups (p<0.01) and
between control and PTX-SLN (p<0.01) groups, where tumor volumes in taxol and PTXSLN groups were smaller than those in the control group. There was no statistically
significant difference in tumor volumes between the control group vs PTX-micelles (p=0.97)
or PTX-liposomes (p=0.99). When comparing the treatment groups, PTX-SLNs
demonstrated statistically significantly smaller tumor sizes compared to PTX-liposomes
(p<0.02) and PTX-micelles (p<0.001). After 24 days of treatment, the percent tumor growth
inhibition was only 9.7% and 20.2% for PTX-micelles and PTX-liposomes compared to the
control (table 5.1). Compared to PTX-micelles and PTX-liposomes, PTX-SLNs inhibited the
tumor growth as much as 50.3% (table 5.1). At the end of the study, the reduction in tumor
mass was the lowest for mice treated with PTX-SLNs and the largest for mice in the control,
PTX-micelles and PTX-liposome groups (figure 5.2, table 5.2). These tumor mass results
correlated well the measured tumor volumes at the end of the study (R2=0.93) (figure 5.3).
For all groups, there was no significant body weight loss observed (figure 5.4). The results
shown in figure 5.5 and 5.6 show that the tumor growth inhibition effect of PTX-micelles,
PTX-liposomes and PTX-SLNs correlate well with the in vitro t50% (R2=0.94) and the in vitro
rate constants in human serum (R2=0.65). Overall, the results showed that PTX-SLNs
demonstrated higher therapeutic efficacy compared to PTX-micelles and PTX-liposomes. A
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plausible conclusion from the in vitro-in vivo correlation results is that the t50% and rate
constants determined in human serum is indicative of the ability of the nanocarrier to stay in
the blood circulation, leading to higher drug concentrations in the tumor and thus increased
efficacy.
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Figure 5.1: Graph showing the average tumor volume over 29 days for mice treated with
trehalose, Taxol, PTX-micelles, PTX-liposomes and PTX-solid lipid nanoparticles (n=8)

Table 5.1: Percent tumor growth inhibition values with respect to control at 24 days
Nanocarrier

% tumor growth inhibition with respect to control at 24 days

PTX-micelles

9.7

PTX-liposomes

20.2

PTX-SLN

50.3
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Figure 5.2: Graph showing the terminal tumor mass at the end of the study for the various
treatments
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Table 5.2: Average tumor mass at the end of the study for mice treated with trehalose, Taxol,
PTX-micelles, PTX-liposomes and PTX-solid lipid nanoparticles
Formulation

Average tumor mass
at the end of the study (grams)

Trehalose

2.38 ± 1.95

PTX-micelles

2.31 ± 1.81

PTX-liposomes

2.23 ± 1.57

Taxol

1.76 ± 1.21

PTX-SLN

1.55 ± 0.85
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Figure 5.3: Graph showing the correlation between tumor mass and tumor volume at the end
of the study

Figure 5.4: Average body weights of mice treated with trehalose, Taxol, PTX-micelles, PTXliposomes and PTX-solid lipid nanoparticles
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Figure 5.5: Graph demonstrating in vitro-in vivo correlation between time to release 50% of
drug (t50%) and percent tumor growth inhibition for PTX-micelles, PTX-liposomes and PTXsolid lipid nanoparticles
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Figure 5.6: Graph demonstrating in vitro-in vivo correlation between rate constants and
percent tumor growth inhibition for PTX-micelles, PTX-liposomes and PTX-solid lipid
nanoparticles
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Chapter 6: Summary and Conclusions
Cancer is one of the major causes of death worldwide and chemotherapy is the
mainstay of treatment. However, conventional chemotherapy has limitations such as the
development of multidrug resistance, low selectivity for target tissue and toxic side effects
that have negative consequences for the health and well-being of cancer patients. Many
chemotherapeutic agents such as paclitaxel have poor aqueous solubility, requiring the use of
other excipients to aid solubilization for effective intravenous administration. For example,
paclitaxel (Taxol) is currently formulated with cremophor EL, which is a toxic excipient and
has been known to cause severe side effects [38]. To overcome these challenges,
nanocarriers can be used to encapsulate and deliver hydrophobic anti-cancer agents to tumor
tissue by passive and active targeting mechanisms. Despite these advantages, premature drug
leakage is one of the major reasons for inefficient drug delivery to the tumor. Drug diffusion
out of the nanocarriers or destabilization of drug loaded nanocarriers by physiological
interactions with blood cells, serum proteins, and cell membranes upon systemic
administration contribute to premature drug release. Therefore, developing stable anti-cancer
nanocarriers is key for the successful clinical translation of these nanomedicines.
In this study, targeted micelles, liposomes and SLNs of similar composition were
prepared and their potential was evaluated by comparing physicochemical characteristics, in
vitro stability, in vitro release rates and in vivo efficacy. Micelles were formed through the
self-assembly of PAs comprising of an LDV peptide region conjugated to single chain
palmitic acid via PEG2 hydrophilic linkers. PAs self-assembled in aqueous solution at CMC
values ranging between 23.68 ± 0.72µM to 38.76 ± 2.27µM. Liposomes and SLNs of similar
composition to micelles were prepared using palmitic acid derived lipids and PAs to impart
targeting properties. In the vitro stability studies using FRET showed that targeted micelles,
liposomes and SLNs were stable when diluted in aqueous medium over 24 hours, however
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the stability decreased in the presence of human serum, where micelles were the least stable
and SLNs the most stable. The same trend was observed for the in vitro paclitaxel release
profiles, where targeted PTX-micelles had the fastest release rate and PTX-SLNs exhibited
the slowest release rate. PTX-micelles, PTX-liposomes and PTX-SLNs were spray dried to
arrest drug passive diffusion and enhance long term stability. The results showed that
compared to initial aqueous dispersions, spray dried formulations maintained their nanosize
and paclitaxel content over 7 days at 4⁰C. At room temperature, the paclitaxel content of
PTX-micelle/trehalose and PTX-SLN/trehalose formulations were maintained over 7 days
and all formulations maintained their nanosize. PTX-micelles, PTX-liposomes and PTXSLNs were further evaluated to determine the anti-cancer in vivo efficacy in an A375
melanoma xenograft mouse model. The results showed a significant delay in tumor growth
for mice treated with PTX-SLNs compared with control, PTX-micelle and PTX-liposome
groups. Overall, the in vitro results showed that targeted PTX-SLNs were the least prone to
disruption in human serum and were able to encapsulate paclitaxel over longer periods of
time under sink conditions compared to PTX-micelles and PTX-liposomes. Furthermore,
PTX-SLNs demonstrated superior anti-cancer efficacy in vivo compared to PTX-micelles
and PTX-liposomes and could be promising vehicles for drug targeting and delivery. Future
work could involve exploring other nanocarriers for stability characterization. The use of
other materials for nanocarrier preparation such as polymers could be investigated.
Additionally, escalation of dose can be implemented to achieve better therapeutic efficacy
with tumor regression.
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